Journal of Advanced Research 24 (2020) 223-238



Contents lists available at ScienceDirect

Journal of Advanced Research

journal homepage: www.elsevier.com/locate/jare



Attenuation of increased intraocular pressure with propofol anesthesia: A systematic review with meta-analysis and trial sequential analysis



Chun-Yu Chang^a, Yung-Jiun Chien^b, Meng-Yu Wu^{c,d,*}

^a School of Medicine, Tzu Chi University, Hualien 970, Taiwan

^b Department of Physical Medicine and Rehabilitation, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan

^c Department of Emergency Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan

^d Department of Emergency Medicine, School of Medicine, Tzu Chi University, Hualien 970, Taiwan

G R A P H I C A L A B S T R A C T

This study provides an overview of intraocular pressure (IOP) changes due to surgery and anesthesia. Intubation and pneumoperitoneum with CO_2 are associated with increased IOP. Trendelenburg, prone, and lateral decubitus positions are associated with increased IOP. Propofol-based total intravenous anesthesia (TIVA) attenuates elevated IOP, and may reduce postoperative visual loss.

		v	leighted mean difference	(95% C	D		
		4	-6 0	+6	Favor	Conclusi	ve NNT
	After induction	242	-+-		NS		
	After intubation	214			Propofol-TIV/	A 🗸	7.60
4	After pneumoperitoneum	172	+		Propofol-TIV/	A 🗸	3.24
2	After Trendelenburg position	264	+		Propofol-TIV/	A 🗸	2.33
	After lateral decubitus position	74			Propofol-TIV/	A V	5.57
	After prone position	84			NS		
			-10 0	+10			
8	After intubation	74			NS		
ō	After lateral decubitus position	74			NS		
_			6 0	+6			
	After induction	178			NS		
0	After intubation	152	+		NS		
<u>Ч</u>	After pneumoperitoneum	204	-		NS		
-	After Trendelenburg position	172	-		NS		
	After lateral decubitus position	74			NS		
_			6 0	+6			
	After induction	202			NS		
₽	After intubation	92			Propotol-TIV/	A V	6.15
<u>a</u>	After pneumoperitoneum	106	-		NS		
	After Trendelenburg position	198			NS		
_			-12 0	+12			
	After induction	433	+		NS		
	After intubation	262			Propofol-TIV/	A 🗸	7.44
AP	After pneumoperitoneum	204	+		Volatile		51.86
Σ	After Trendelenburg position	285			NS		
	After reverse Trendelenburg position	82			NS		
	After lateral decubitus position	84			NS		
	After resolution of pneumoperitoneum	189			NS		

ARTICLE INFO

Article history: Received 17 October 2019 Revised 28 January 2020 Accepted 11 February 2020 Available online 13 February 2020

Keywords: Anesthesia Intraocular pressure Meta-analysis

ABSTRACT

Attenuation of an increase in intraocular pressure (IOP) is crucial to preventing devastating postoperative visual loss following surgery. IOP is affected by several factors, including the physiologic alteration due to pneumoperitoneum and patient positioning and differences in anesthetic regimens. This study aimed to investigate the effects of propofol-based total intravenous anesthesia (TIVA) and volatile anesthesia on IOP. We searched multiple databases for relevant studies published before October 2019. Randomized controlled trials comparing the effects of propofol-based TIVA and volatile anesthesia on IOP during surgery were considered eligible for inclusion. Twenty studies comprising 980 patients were included. The mean IOP was significantly lower in the propofol-based TIVA group after intubation, pneumoperitoneum, Trendelenburg positioning, and lateral decubitus positioning. Moreover, mean arterial pressure and peak

Peer review under responsibility of Cairo University.

* Corresponding author at: Department of Emergency Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan. *E-mail address:* skyshangrila@gmail.com (M.-Y. Wu).

https://doi.org/10.1016/j.jare.2020.02.008

^{2090-1232/© 2020} THE AUTHORS. Published by Elsevier BV on behalf of Cairo University.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Propofol Trial sequential analysis inspiratory pressure were also lower after intubation in the propofol-based TIVA group. Trial sequential analyses for these outcomes were conclusive. Propofol-based TIVA is more effective than volatile anesthesia during surgery at attenuating the elevation of IOP and should be considered, especially in atrisk patients.

© 2020 THE AUTHORS. Published by Elsevier BV on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Intraocular pressure (IOP) is a crucial parameter in determining the ocular perfusion pressure (OPP) during surgery. IOP is affected by several factors, including aqueous humor and choroidal blood volumes, mean arterial pressure (MAP) [1], extraocular muscle (EOM) tone controlled by central diencephalic centers [2], hypercapnia [3], coughing, straining, and vomiting [4]. In addition, with the advent of laparoscopic and robotic surgery, the physiologic change after carbon dioxide (CO₂) pneumoperitoneum and Trendelenburg positioning also affect IOP [5,6]. An increase in IOP blocks the retrograde transport of neutrophilic factors from the brain [7], reduces ocular blood flow [8], leads to optic nerve edema and ischemia [6,9], and may result in rare but catastrophic postoperative visual loss (POVL) [10].

Anesthetic techniques can help attenuate the increase in IOP in several ways. Most intravenous and volatile anesthetics decrease IOP to some extent. The mechanisms underlying such a phenomenon include decreased choroidal blood volume due to decreased blood pressure [11], decreased ocular wall tension due to relaxation of the EOM via depression of the central diencephalic centers [2], decreased formation of aqueous humor, and the facilitation of aqueous outflow [12,13]. Depolarizing neuromuscular blocking agents (NMBAs) has been known to cause an IOP increase due to fasciculation of the EOM [14], whereas non-depolarizing NMBAs demonstrated a comparatively lower IOP [15]. Shortacting opioids, such as fentanyl, alfentanil [16], sufentanil [17], and remifentanil [18], decrease IOP at induction. Previous studies investigated the effects of propofol-based total intravenous anesthesia (TIVA) and volatile anesthesia (VA) on IOP during surgery, but the results are inconclusive. Thus, we conducted this metaanalysis to evaluate the most recent studies and determine whether different anesthetic techniques for maintenance influence IOP.

Material and methods

Study design

This meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the effects of propofol-based TIVA versus VA on IOP in patients undergoing surgery. This study complies with the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement [19]. Ethical committee approval was not required for this meta-analysis.

Eligibility criteria

Patients aged \geq 18 years scheduled for elective surgery were considered eligible for this study. We excluded patients who underwent previous eye surgery or had a medical history of glaucoma, uncontrolled hypertension, chronic obstructive lung disease, a known allergy to anesthetics, or a history taking medications known to alter IOP.

Search strategy

PubMed, EMBASE, Cochrane Library, and Scopus databases were searched through October 2019. MeSH terms including "Intraocular Pressure"[Mesh], "Anesthesia, Intravenous"[Mesh], "propofol" [Mesh], "Anesthesia, Inhalation"[Mesh], "desflurane"[Mesh], "sevoflurane"[Mesh], "isoflurane"[Mesh], "enflurane"[Mesh], "halothane"[Mesh] and "Balanced Anesthesia"[Mesh] were used in combination with plain text to search PubMed. Similar strategies were applied to search the other databases. A detailed description of the search strategies is provided in Supplement 1. The reference lists of the included studies were manually searched to identify additional studies.

Study selection

All studies were selected by two independent reviewers (C.Y. Chang and Y.J. Chien) according to the following criteria, with all conditions being met: (a) study of RCTs involving adult patients undergoing elective surgery; (b) study including clinical outcomes of interest, i.e., IOP. We did not exclude studies by date, region, or language. A third reviewer (M.Y. Wu) provided consensus or discussion in cases of disagreement.

Risk of bias assessment

The methodological quality of the RCTs was assessed using RoB 2, a revised tool for assessing risk of bias in randomized trials [20]. Two reviewers (C.Y. Chang and Y.J. Chien) independently evaluated the methodological quality of the included studies. Disagreements were resolved through consensus or discussion with a third reviewer (M.Y. Wu).

Data collection

Data sets were extracted by two independent reviewers (C.Y. Chang and Y.J. Chien) from each eligible study. The required information included the first author's name, publication year, surgery type, age, sex, regimen for anesthesia induction and maintenance, outcomes of interest, and the protocol for measuring IOP. In circumstances in which the data were insufficient for metaanalysis, efforts were made to contact the authors of the original articles for additional information.

Statistics

The efficacy was estimated for each study by the mean difference and its 95% confidence interval (CI). The weighted mean difference (WMD) and 95% CI were calculated using the inverse variance method with a random-effects model (DerSimonian-Laird estimator [21]). Statistical heterogeneity was assessed by the Cochran Q statistic and quantified by the I² statistic. A subgroup analysis was conducted to examine whether different intravenous anesthetics used for induction in the volatile anesthesia group could have confounded the IOP or MAP after induction and intubation. A sensitivity analysis using influence analysis (leaveone-out method) and replacing one outcome measurement with another after the same event but for a different duration (e.g., outcome of interest measured at 5 and 60 min after lateral decubitus positioning [LDP]) was conducted to test the robustness of the results. Trial sequential analysis (TSA) was conducted to estimate the information size required for a conclusive meta-analysis and evaluate whether the results were subject to type I error due to an insufficient number of included studies [22]. In the TSA, type I error was set at 5%, power was set at 80%, and a heterogeneity adjustment factor was incorporated into the estimation of the required information size (RIS). Cohen's d was calculated in the outcomes with significant intergroup differences yielded from the meta-analysis. Number-needed-to-treat (NNT) was obtained from Cohen's d using Furukawa's method with the control event rate set at 20% [23]. The data synthesis and subgroup analysis were performed using Review Manager software (version 5.3; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). The sensitivity analysis was performed using R version 3.6.1 with the "meta" package. The TSA was conducted using TSA software (version 0.9.5.10 Beta). P values <0.05 were considered statistically significant.

Results

Study selection

A total of 348 studies were identified from four major databases, including PubMed (n = 49), EMBASE (n = 134), Cochrane (n = 52), and Scopus (n = 113). One additional record was identified through a Google search. After the removal of 179 duplicates, the remaining studies were screened for eligibility. One hundred and forty-one studies were excluded due to being irrelevant, animal studies, conference abstracts, or other reasons listed in Fig. 1. As a result. 29 studies were subjected to full-text review. However, one article was excluded because it did not compare propofolbased TIVA with VA, while another 8 articles were excluded because the full text could not be retrieved. Finally, 20 studies comprising 980 patients were included in the qualitative synthesis. Four studies [24–27] were not included in the further quantitative analysis due to insufficient information despite direct contact of the authors, leaving 16 studies included in the meta-analysis. The detailed PRISMA flow diagram is shown in Fig. 1.

Study characteristics

Eight studies enrolled patients undergoing laparoscopic surgery, including lower abdominal surgery [28], colorectal surgery [29], radical prostatectomy [30], cholecystectomy [31,32], pelvic surgery [32], and gynecological surgery [25,33,34]. Six studies enrolled patients undergoing ophthalmic surgery, including cataract surgery [24,35,36], anterior segment surgery [37], a variety of ophthalmic surgeries [38], and unspecified ophthalmic surgery [39]. Two studies enrolled patients undergoing spine surgery in the prone position [40,41]. Two studies enrolled patients undergoing orthopedic surgery, thoracic surgery, and nephrectomy requiring LDP [42,43]. One study enrolled patients undergoing open gynecological or urological surgery [27]. One study enrolled patients undergoing unspecified non-ophthalmic surgery [26]. Overall, the mean patient age ranged from 30.9 [25] to 74.5 [36] vears. In studies in which the patients underwent ophthalmic surgery, the mean age ranged from 56.5 [24] to 74.5 [36] years, while in studies in which the patients underwent laparoscopic surgery, the mean age ranged from 30.9 [25] to 64.9 [30] years. IOP was measured with/without topical anesthetics. In ophthalmic surgery, IOP was measured only in the non-operated eye in five studies [24,35–37,39] and was measured in both eyes before the surgical procedures and in the non-operated eye at the end of surgery in one study [38]. In non-ophthalmic surgery, IOP was measured in both eyes in seven studies [28,29,31,32,40,42,43], while the rest did not specify which eye was measured. All studies used an endotracheal tube for intubation except for one that used a laryngeal mask airway [36] and one that did not specify [26]. Sevoflurane was used for maintenance in the VA group in seven studies [27,28,30,34,35,41,43], desflurane in six studies [26,29,31-33,42], isoflurane in seven studies [24-26,36,37,39,40], and enflurane in one study [38]. Depolarizing NMBA was only used in two studies facilitate endotracheal intubation [34,39], while nonto depolarizing NMBA was used in the rest of the studies. The Hwang et al. study [32] enrolled patients undergoing surgery involving



Fig. 1. PRISMA flow diagram.

two different intraoperative positions, Trendelenburg and reverse Trendelenburg, which may have distinct effects on IOP. Accordingly, the Hwang et al. study was considered two individual studies for the further analysis and discussion (denoted as Hwang 2013-T and Hwang 2013-RT, respectively). A brief summary of the study characteristics is shown in Table 1.

Risk of bias

Six studies were considered as having a low risk of bias. Some concerns for bias were raised in 13 studies due to insufficient information for judgment regarding the blinding of the outcome assessors, which could possibly (although unlikely) influence the intergroup outcome assessment. The Mirkheshti [40] study was considered as having a high risk of bias in that the baseline demographics showed significant intergroup differences in IOP (16 ± 3 in the isoflurane group versus 18 ± 5 in the propofol-based TIVA group, P = 0.02) and sex (66.7% male in the isoflurane group versus 26.7% male in the propofol-based TIVA group, P = 0.002), suggesting a problem with the randomization process. The risk of bias graph and summary are shown in Fig. 2.

Intraocular pressure

IOP values were reported in six studies (n = 242) after induction, six studies (n = 214) after intubation, three studies (n = 172) after CO_2 pneumoperitoneum, five studies (n = 264) after Trendelenburg positioning, two studies (n = 74) after LDP, and two studies (n = 84)after prone positioning. The pooled effect estimate showed a significantly lower IOP in the propofol-based TIVA group versus the volatile group after intubation (WMD, -1.87; 95% CI, -3.32 to -0.42; P = 0.01), after CO₂ pneumoperitoneum (WMD, -2.83; 95% CI, -3.27 to -2.38; P < 0.01), after Trendelenburg positioning (WMD, -4.23; 95% CI, -4.70 to -3.75; P < 0.01), and after LDP (WMD, -1.95; 95% CI, -3.15 to -0.75; P < 0.01). In the induction and prone positions, the pooled effect estimate showed no significant difference in IOP (Fig. 3). A sensitivity analysis was also performed with exclusion of the Mirkheshti et al. study [40] because the baseline IOP in the propofol-based TIVA group was significantly higher than that in the volatile-based anesthesia group. The pooled effect estimate after induction remained non-significant after the exclusion of this study (WMD, -0.98; 95% CI, -2.65 to 0.68; P = 0.25)

In the TSA of induction, the cumulative Z-curve surpassed the traditional boundary for statistical significance after the Schafer et al. study [35] and the Sugata et al. study [41] but fell within the traditional boundaries thereafter. The adjusted boundary for the significance threshold was ignored due to too little information use (1.95%). In the TSA of intubation, the cumulative Z-curve surpassed the upper sequential monitoring boundary for the adjusted statistical significance threshold (TSA-adjusted CI, -3.55 to -0.19; calculated Cohen's d, -0.406; NNT, 7.60). In the TSA of LDP, the cumulative Z-curve reached the RIS and surpassed the traditional significance boundary (TSA-adjusted CI, -3.80 to -0.10; calculated Cohen's d, -0.535; NNT, 5.57). In the TSA of CO₂ pneumoperitoneum and Trendelenburg positioning, the estimated RIS was exceeded by the first information; thus, the sequential monitoring boundaries were not renderable. The cumulative Z-curve surpassed the traditional significance boundary (calculated Cohen's d, -0.862; and NNT, 3.24 in CO₂ pneumoperitoneum; calculated Cohen's d, -1.168; and NNT, 2.33 in Trendelenburg positioning). In the TSA of the prone position, the estimated RIS was not reached by the cumulative Z-curve and the cumulative Z-curve did not surpass the traditional boundary (TSA-adjusted CI was -6.04 to 2.81) (Suppl. Fig. S2).

In the propofol-TIVA group, propofol was used for induction in all studies. However, in the VA group, etomidate was used in two studies [36,37], thiopental in three [29,38,42], and propofol in one [43] for induction. The subgroup analysis showed that IOP after intubation in the propofol-TIVA group was significantly lower than that in the VA group with thiopental as the induction agent (WMD, -2.94; 95% CI, -4.42 to -1.46; P < 0.01). However, IOP was not significantly different in the propofol-TIVA group versus the VA group with etomidate (WMD, -0.39; 95% CI, -3.62 to 2.85; P = 0.82) and propofol (WMD, -2.00; 95% CI, -5.31 to 1.31; P = 0.24) as the induction agent (Suppl. Fig. S3).

Ocular perfusion pressure

Only two studies reported ocular perfusion pressure (OPP) measured after intubation and LDP. The pooled effect estimate showed no significant difference after intubation (WMD, -3.39: 95% CI. -8.85 to 2.07; P = 0.22) and LDP (WMD, -1.36; 95% CI, -8.79 to 6.07; P = 0.72) (Fig. 4). In the TSA of intubation, the cumulative Z-curve did not reach the estimated RIS and did not surpass the traditional boundary for statistical significance or the sequential monitoring boundary for the adjusted significance threshold (TSA-adjusted CI, -17.23 to 10.44). In the TSA of LDP, the cumulative Z-curve did not surpass the traditional boundary for statistical significance. The sequential monitoring boundary for the adjusted significance threshold was ignored due to too little information used (1.64%) (Suppl. Fig. S4). In the sensitivity analysis, we replaced the OPP measured at 5 min after the adoption of LDP with that measured at 1 h after LDP reported in the Yamada et al. [43] study to evaluate if the effect of the propofol-based TIVA and the volatile-based anesthesia on OPP was influenced by the duration of the positional change. The intergroup difference in the pooled effect estimate remained non-significant (WMD, 2.56; 95% Cl, -2.64 to 7.75; P = 0.33).

End-tidal CO₂

End-tidal CO₂ was investigated in four studies (n = 178) after induction, four (n = 152) after intubation, four (n = 204) after pneumoperitoneum, three (n = 172) after Trendelenburg positioning, and two (n = 74) after LDP. The pooled effect estimate showed no significant difference in IOP after induction (WMD, 0.83; 95% CI, -0.39 to 2.05; P = 0.18), after intubation (WMD, -0.02; 95% CI, -0.55 to 0.52; P = 0.96), after pneumoperitoneum (WMD, -0.48; 95% CI, -1.22 to 0.25; P = 0.20), after Trendelenburg positioning (WMD, -0.34; 95% CI, -1.00 to 0.32; P = 0.32), and after LDP (WMD, -1.82; 95% CI, -5.07 to 1.43; P = 0.27) (Fig. 5).

In the TSA, the cumulative Z-curve did not reach the estimated RIS and did not surpass the sequential monitoring boundary for the adjusted significance threshold after induction (TSA-adjusted CI, -1.92 to 3.58), after pneumoperitoneum (TSA-adjusted CI, -2.29 to 1.32), after Trendelenburg positioning (TSA-adjusted CI, -3.03 to 2.36), and after LDP (TSA-adjusted CI, -15.09 to 11.44). In the TSA of intubation, the cumulative Z-curve did not surpass the traditional significance boundary, and the sequential monitoring boundary for adjusted significance threshold was ignored due to too little information used (0.07%) (Suppl. Fig. S5).

Peak inspiratory pressure

Peak inspiratory pressure (PIP) was analyzed in four studies (n = 202) after induction, two (n = 92) after intubation, two (n = 106) after pneumoperitoneum, and four (n = 198) after Trendelenburg positioning. The pooled effect estimate showed no significant intergroup difference in IOP after induction (WMD, 0.07; 95% CI, -0.33 to 0.47; P = 0.74), after pneumoperitoneum (WMD,

Table 1

Study characteristics.

Study	Surgery	argery Position <u>Number</u>		VA	Age		Sex Regimen		Airway	Tonometer
			P- VA (n) TIVA (n)		P-TIVA	VA	M F P-TIVA (n) (n)	VA	-	
Kim 2019	Arthroscopic shoulder surgery	Lateral decubitus	23 23	Desflurane	59.22(7.70)	59.17(8.50)	 21 25 <u>Induction:</u> propofol 1.5– 2.5 mg/kg, remifentanil continuous infusion and rocuronium 1 mg/kg. <u>Maintenance:</u> continuous infusion of 2% propofol and remifentanil. Propofol was administered via a TCI syst with Cet 2.5–5 mg/ml. 	Induction: thiopenta 5–6 mg/kg, remifentanil continuous infusion and rocuronium 1 mg/kg. Maintenance: PM Desflurane 5–8 vol% and continuous infusion of remifentanil using a TCI system with Cet 3–6 ng/ml.	I ETT	Tono-Pen [®] AVIA, Reichert Technologies, Depew, NY, USA
Kaur 2018	Lower abdominal laparoscopic surger	25°–30° y Trendelenburg position	30 30	Sevoflurar	e 30.53(11.05)	31.87(11.81)) 29 31 <u>Induction:</u> propofol 1.5 mg fentanyl 2 μg, midazolam 1 mg, atracurium 0.5 mg/k <u>Maintenance:</u> propofol infusion 5–10 mg/kg/h	kg, <u>Induction:</u> propofol 1.5 mg/kg, fentanyl 2 µg, midazolam 1 mg, atracurium 0.5 mg/kg. <u>Maintenance:</u> sevoflurane 1–4 vol%	ETT	Schiotz tonometer
Seo 2018	Laparoscopic anterior resection of the sigmoid colon; laparoscopic low anterior resection of the rectum	Supine- f Trendelenburg (30° with right tilt (10°- 15°)-reverse f Trendelenburg (20°-25°) with righ tilt-Trendelenburg with right tilt	23 23) t	Desflurane	58.43(7.39)	59.61(9.67)	30 16 <u>Induction:</u> propofol 1.5– 2.5 mg/kg, rocuronium 1 m kg. <u>Maintenance:</u> propofol TCI (Cet: 2.5–5 μg/mL), remifentanil TCI (Cet:3–6 r mL).	Induction: thiopenta g/ 5-6 mg/kg, rocuronium 1 mg/kg <u>Maintenance:</u> desflurane 5-8 vol%, remifentanil TCI (Cet:3-6 ng/mL).	1 ETT	Tono Pen [®] AVIA, Reichert Technologies, Depew, NY, USA
Mirkheshti 2017	Lumbar disc herniation surgery	Prone	30 30	Isoflurane	46.5(12)	47.3(9)	 28 32 <u>Induction:</u> thiopental 5 mg fentanyl 2 µg/kg, midazola 0.02 mg/kg, atracurium 0.5 mg/kg. <u>Maintenance:</u> propofol 100 200 µg/kg/min 	 kg, <u>Induction</u>: thiopenta n 5 mg/kg, fentanyl 2 μg/kg, midazolam 0.02 mg/kg, atracurium 0.5 mg/kg. <u>Maintenance</u>: 	1 ETT	Tono-Pen AVIA, Reichert, USA
Yamada 2016	Sevoflurane group: lung operation, hip replacement, femoral plate removal Propofol group: lun operation, nephrectomy	Lateral decubitus	14 14	Sevofluran	e 66.1(7.5)	63.5(16)	 13 15 <u>Induction:</u> propofol TCI (Ce 3.0–5.0 μg/ml), remifentan 0.2–0.5 μg/kg/min, vecuronium (0.12–0.15 mg or rocuronium (0.65–0.9 m kg). <u>Maintenance:</u> propofol TCI (Cet: 2.8–4 μg/ml), fentany 50–100 μg bolus and/or remifentanil 0.1–0.3 μg/kg, min infusion as needed. 	 Induction: 1.8- 2.5 mg/kg propofol bolus, remifentanil kg) 0.2-0.5 μg/kg/min, vecuronium (0.12- 0.15 mg/kg) or rocuronium (0.65- 0.9 mg/kg). Maintenance: sevoflurane 1.5- 2.0 vol%, fentanyl 50 100 μg bolus and/or 	ETT	Tono-Pen® XL Applanation tonometer (Reichert, Depew, NY, USA)

C.-Y. Chang et al./Journal of Advanced Research 24 (2020) 223–238

(continued on next page)

Table 1 (continued)

Study	Surgery	Position	Num	ber	VA	Age		Sex	Regimen		Airway	Tonometer
			P- TIVA (n)	VA (n)	-	P-TIVA	VA	M F (n) (n)	P-TIVA	VA	-	
										remifentanil 0.1– 0.3 μg/kg/min infusion as needed.		
Montazeri 2015	Cataract surgery	-	67	67	Isoflurane	With remifentanil: 58.7(13.4) With normal saline: 62.7 (7.1)	With remifentanil: 54.2(12.3) With normal saline: 60.6 (13.9)	50 84	Induction: thiopental 5 mg/kg remifentanil 1 µg/kg, atracurium 0.5 mg/kg. <u>Maintenance:</u> propofol 100 µg kg/min with either remifentanil 0.1 µg/kg/min or normal saline.	. Induction: thiopental 5 mg/kg, remifentanii 1 μg/kg, atracurium (0.5 mg/kg. <u>Maintenance:</u> isoflurane with either remifentanil 0.1 μg/ kg/min or normal saline.	ETT	Handheld applanation tonometer
Yoo 2014	Robot-assisted laparoscopic radica prostatectomy	30° Trendelenburg I position	33	33	Sevoflurane	2 64.7(8.3)	65.1(6.7)		Propofol TCI (Cet: 2–5 µg/ml) and remifentanil TCI (Cet: 2– 5 ng/ml) for induction and maintenance. Rocuronium 0.6 mg/kg for intubation, rocuronium 0.15 mg/kg during maintenance as needed.	Induction: propofol 1.5 mg/kg bolus, remifentanil, rocuronium 0.6 mg/ kg. Maintenance: sevoflurane 1.5- 2.5 vol%, remifentanii TCI (Cet: 2–5 ng/ml), rocuronium 0.15 mg/ kg as needed.	ETT	Tono-Pen [®] XL, Medtronic, Jacksonville, FL, USA
Asuman 2013	Laparoscopic cholecystectomy	15° reverse Trendelenburg	14	18	Desflurane	49.57(9.93)	46.33(11.32)	11 21	<u>Induction:</u> propofol 2 mg/kg, rocuronium 0.6 mg/kg. <u>Maintenance:</u> propofol infusion 5–10 mg/kg/h, fentanyl 0.5–1 μg/kg as needed	Induction: thiopental 5 mg/kg, rocuronium 0.6 mg/kg. <u>Maintenance:</u> desflurane 3–6 vol%, fentanyl 0.5–1 μg/kg as needed	ETT	Shioetz tonometer
Hwang 2013-RT	Laparoscopic cholecystectomy	20° reverse Trendelenburg position	25	25	Desflurane	51(14)	54(15)		<u>Induction:</u> propofol TCI (Cet: 4 mg/mL), alfentanil 6 mg/kg, rocuronium 0.6 mg/kg. <u>Maintenance:</u> propofol TCI (Cet: 2–4 mg/mL).	Induction: thiopental 5 mg/kg, alfentanil 6 mg/kg, rocuronium 0.6 mg/kg. Maintenance: desflurane 4–8 vol%.	ETT	Tono-penXL (Medtronicsolan, Jacksonville, FL)
Hwang 2013-T	Pelvic laparoscopy	20° Trendelenburg position	25	25	Desflurane	42(11)	41(8)		Induction: propofol TCI (Cet: 4 mg/mL), alfentanil 6 mg/kg, rocuronium 0.6 mg/kg. <u>Maintenance:</u> propofol TCI (Cet: 2–4 mg/mL).	Induction: thiopental 5 mg/kg, alfentanil 6 mg/kg, rocuronium 0.6 mg/kg. <u>Maintenance:</u> desflurane 4–8 vol%.	ETT	Tono-penXL (Medtronicsolan, Jacksonville, FL)
Sugata 2012	Prone spine surgery	/ Prone	12	12	Sevoflurane	2 68(12)	69(10)	14 10	Induction: TCI doses of propofol and remifentanil 0.2- 0.3 mg/kg/min, vecuronium or rocuronium to facilitate intubation. <u>Maintenance:</u> TCI of propofol, fentanyl, and remifentanil 0.15–0.2 mg/kg/min.	Induction: propofol 1.5-2.5 mg/kg, remifentanil 0.2- 0.3 mg/kg/min, vecuronium or rocuronium to facilitate intubation. Maintenance:	ETT	Tonopen XL hand-held tonometer (Medtronic SOLAN, Jacksonville, FL)

C.-Y. Chang et al./Journal of Advanced Research 24 (2020) 223–238

228

Table 1 (continued)

Study	Surgery	Position	Num	ber	VA	Age		Sex		Regimen		Airway	Tonometer
			P- TIVA (n)	VA (n)		P-TIVA	VA	M F (n) (1	[n)	P-TIVA	VA		
Park 2006	Laparoscopic gynecological surgery	10° Trendelenburg position	21	21	Desflurane	42.0(11.1)	40.6(8.3)	04	42	<u>Induction:</u> propofol TCI (Cet: 4 µg/ml), alfentanil 6 µg/kg, rocuronium 0.6 mg/kg. <u>Maintenance:</u> propolol TCI (Cet: 2.5.4 µg/mplo)	sevoflurane (concentration no specified), fentanyl, and remifentanil 0.15–0.2 mg/kg/min <u>Induction</u> : thiopental 5 mg/kg, alfentanil 6 µg/kg, rocuronium 0.6 mg/kg.	ETT	Tono-penRXL, Medtronicsolan, Jacksonville, FL, USA).
Son 2005	Laparoscopic hysterectomy	15°–20° Trendelenburg	15	16	Sevoflurane	42.7(6.1)	44.3(7.6)		_	Induction: propofol TCI (Cet: 5 µg/ml), fentanyl 1.5 µg/kg, succinylcholine 1 mg/kg. <u>Maintenance:</u> propofol TCI (Cet: 3–4.5 µg/ml), vecuronium	desflurane 4–8 vol%. Induction: thiopental 5 mg/kg, fentanyl 1.5 mg/kg, succinylcholine 1 mg/ kg. <u>Maintenance:</u> sevoflurane (1.5– 3 vol%), vecuronium	ETT	Tono-pen tonometer (Tono- pen XLR, Mentor O & O inc, USA) after one dose of 0.5% proparacaine hydrochloride
Mowafi 2003	Gynecologic laparoscopy	15°-20° Trendelenburg position	20	20	lsoflurane	30(7.1)	31.8(6.0)		_	Induction: propofol 2.5 mg/kg, fentanyl 2 µg/kg, atracurium 0.5 mg/kg. <u>Maintenance:</u> propofol infusion 5–10 mg/kg/hr, atracurium 0.15 mg/kg as needed.	Induction: thiopental 5 mg/kg, fentanyl 2 μg/kg, atracurium 0.5 mg/kg. <u>Maintenance:</u> isoflurane 1–2 vol%, atracurium 0.15 mg/ kg as needed	ETT	Schioetz tonometer
Sator-Katzenschlager 2002	Elective gynaecological or urological procedures	-	16	17	Sevoflurane	-	-		_	<u>Induction:</u> propofol 2 mg/kg, fentanyl 2 µg/kg, vecuronium 0.1 mg/kg. <u>Maintenance:</u> propofol infusion 6–8 mg/kg/hr.	Induction: propofol 2 mg/kg, fentanyl 2 μg/kg, vecuronium 0.1 mg/kg. <u>Maintenance:</u> sevoflurane 1.5– 2.5 vol%.	ETT	Hand-held Perkins applanation tonometer.
Schafer 2002	Cataract surgery	_	20	20	Sevoflurane	71(14)	75(11)	93	31	Induction: propofol 1.5– 2.0 mg/kg bolus, remifentanil 10 mg/kg/h over 2 mins, mivacurium 0.12 mg/kg. <u>Maintenance:</u> propofol 3.0– 7.0 mg/kg/h, remifentanil 10 mg/kg/hr.	Induction: propofol 1.5–2.0 mg/kg bolus, remifentanil 10 mg/ kg/h over 2 mins, mivacurium 0.12 mg/ kg. <u>Maintenance:</u> sevoflurane 0.7– 1.2 vol%, remifentanil 10 mg/kg/hr.	ETT	Draeger handheld applanation tonometer, Moeller-Wedel Inc., 22,668 Wedel, Germany

(continued on next page)

Study	Surgery	Position	Num	ber	VA	Age		Sex	Regimen		Airway	Tonometer
			P- TIVA (n)	VA (n)	-	P-TIVA	VA	M F (n) (n)	P-TIVA	VA	-	
Sator 1998	Elective non- ophthalmic surgery	-	16	Isoflurane: 16 Desflurane: 16	Isoflurane, desflurane	-	-		Induction: thiopental 3–5 mg/ kg, vecuronium 0.1 mg/kg, fentanyl 2–4 μg/kg. <u>Maintenance:</u> propofol 4– 8 mg/kg/hr	Induction: thiopental 3–5 mg/kg, vecuronium 0.1 mg/ kg, fentanyl 2–4 μg/ kg. <u>Maintenance:</u> 1 MAC of isoflurane or desflurane	Unspecified	Hand-held applanation tonometer (Perkins)
Moffat 1995	Cataract surgery	-	20	20	Isoflurane	72(range 60– 86)	77(range 64– 88)		Anesthesia was induced and maintained with propofol using a computer-controlled infusion device (target plasma concentration 6 µg/ml -> 4 µg/ ml).	Induction: etomidate 0.25 mg/kg, vecuronium 0.075 mg/kg. <u>Maintenance:</u> isoflurane 0.5–1 vol%	LMA	Perkins tonometer
Polarz 1995	Ophthalmic surgery	. –	20	20	Isoflurane	73.3(7.2)	74.2(8.1)	13 27	<u>Induction:</u> propofol 1.5 mg/kg bolus, alfentanil 15 µg/kg bolus, succinylcholine 1 mg/ kg. <u>Maintenance:</u> propofol 6 mg/ kg/h, alfentanil 15 µg/kg/h, vecuronium 0.07 mg/kg.	Induction: thiopental 4 mg/kg, alfentanil 15 pg/kg, succinylcholine 1 mg/ kg. <u>Maintenance:</u> isoflurane 0.5–0.8 vol %, vecuronium 0.07 mg/kg.	ETT	Möller-Wedel applanation tonometer on health eyes
Mets 1992	Anterior segment surgery	-	20	20	Isoflurane	67.6(8)	70.1(7.1)	18 22	<u>Induction:</u> propofol (2.05 ± 1.07 mg/kg), vecuronium 0.1 mg/kg. <u>Maintenance:</u> propofol 90 μg/ kg/min, vecuronium 0.1 mg/ kg.	Induction: etomidate (0.23 ± 0.09 mg/kg), alfentanil 15 µg/kg, vecuronium 0.1 mg/ kg. <u>Maintenance:</u> isoflurane 0.5%, vecuronium 0.1 mg/ kg.	ETT	Schiotz tonometer
Guedes 1988	Cataract extraction, strabismus, dacryocystectomy, secondary implantation, detachment of the retina, vitrectomy, trabeculectomy	-	15	15	Enflurane	73.6(21)	71.6(0.2)	16 14	Induction: propofol (1.8 ± 0.39 mg/kg) bolus, vecuronium (unspecified dose). <u>Maintenance:</u> propofol continuous infusion (5.2 ± 1.55 mg/kg/hr)	Induction: thiopental 6.8 ± 1.16 mg/kg, vecuronium (unspecified dose). <u>Maintenance:</u> enflurane 1.1 ± 0.39 vol%	ETT	Perkins tonometer

230

C.-Y. Chang et al./Journal of Advanced Research 24 (2020) 223–238

Age is presented as mean (SD). P-TIVA: propofol-based total intravenous anesthesia; VA: volatile anesthesia; M: male; F: female; TCI: target-controlled infusion; Cet: target effect-site concentration; IOP: intraocular pressure; ETT: endotracheal tube; LMA: laryngeal mask airway.





-0.13; 95% CI, -0.92 to 0.65; P = 0.74), and after Trendelenburg positioning (WMD, -0.05; 95% CI, -1.22 to 1.11; P = 0.93). However, after intubation, PIP was significantly lower in the propofolbased TIVA group (WMD, -1.32; 95% CI, -2.53 to -0.29; P = 0.01) (Fig. 6).

In the TSA, the estimated RIS was not reached by the cumulative Z-curve and the cumulative Z-curve did not surpass the traditional boundary for statistical significance after induction, after pneumoperitoneum, and after Trendelenburg positioning. In these three situations, the sequential monitoring boundary for the adjusted significance threshold was ignored due to too little information used (1.49%, 1.35%, and 0.09%). After intubation, the estimated

RIS was 115 and was not reached by the cumulative Z-curve (92). Nonetheless, the cumulative Z-curve surpassed the upper sequential monitoring boundary for the adjusted significance threshold after inclusion of the Kim et al. study [42] (TSA-adjusted CI, -2.51 to -0.14; calculated Cohen's d, -0.490; and NNT, 6.15) (Suppl. Fig. S6).

Mean arterial pressure

MAP was analyzed in 10 studies (n = 433) after induction, seven (n = 262) after intubation, four (n = 204) after pneumoperitoneum, six (n = 285) after Trendelenburg positioning, two (n = 82) after

									Me	an Difference	(95% CI)
		Prop	ofol -	TIVA	V	olati	le		Favor	Favor	
	Study ID	Mean	SD	Total	Mean	SD	Total	Weight -	Propofol -TIVA	Volatile	1
	Guedes 1988	12.6	4.26	15	14.4	6.97	15	10.7%	+		-1.80 [-5.93, 2.33]
	Schafer 2002	6	3.2	20	8.9	3.4	20	19.4%			-2.90 [-4.95, -0.85]
o	Sugata 2012	8.9	3.5	12	11.6	3.9	12	15.1%			-2.70 [-5.66, 0.26]
IJ	Yamada 2016	16	3.5	14	14.4	3.7	14	16.4%	+	•	1.60 [-1.07, 4.27]
qu	Mirkheshti 201	7 17.8	7.8	30	13.36	6.5	30	12.4%			4.44 [0.81, 8.07]
<u> </u>	Kaur 2018	12.39	0.8	30	12.37	0.9	30	26.0%	+		0.02 [-0.41, 0.45]
	Total (95%Cl)			121			121	100%	-	-	-0.35 [-2.10, 1.41]
	Heterogeneity:	Tau² =	3.03;	Chi² = 1	8.63, df	= 5 (F	- = 0.00	02); l² = 739	% Test for overall e	effect: Z = 0.39 (I	P = 0.70)
								-6	5 O	+6	i i i i i i i i i i i i i i i i i i i
	Guedes 1988	13.7	4.65	15	14.8	6.58	15	9.8%			-1.10 [-5.18, 2.98]
	Mets 1992	14.4	3.03	10	16.4	3.6	14	17.7%			-2.00 [-4.66, 0.66]
lo	Moffat 1995	12.4	5.6	20	11.1	3.2	20	16.5%			1.30 [-1.53, 4.13]
at	Yamada 2016	11.9	3.6	14	13.9	5.2	14	13.3%		_	-2.00 [-5.31, 1.31]
qn	Seo 2018	13.91	4.34	23	16.52	4.21	23	19.3%			-2.61 [-5.08, -0.14]
<u>l</u>	Kim 2019	15.39	4.09	23	19.04	2.98	23	23.3%			-3.65 [-5.72, -1.58]
	Total (95%Cl)			105			109	100%			-1.87 [-3.32, -0.42]
	Heterogeneity:	Tau ² =	1.23;	Chi² = 8	3.10, df	= 5 (P	= 0.15); I² = 38%	Test for overall eff	ect: Z = 2.53 (P	= 0.01)
								-6	5 0	+6	
Υ E	Yoo 2014	15	3.4	33	18.4	5.6	33	4.0%			-3.40 [-5.64, -1.16]
nel nel	Kaur 2018	14.1	0.7	30	16.9	1.1	30	92.0%			-2.80 [-3.27, -2.33]
ito	Seo 2018	10.91	2.81	23	13.78	4.69	23	4.0%			-2.87 [-5.10, -0.64]
Pel Pi	Hotorogonoity:	Tou ² -	0.00.	$Chi^2 = ($) 27 df -	- 2 (P	- 0.99	100%	Test for overall effe	oct: 7 - 12 38 /P	-2.63 [-3.27, -2.36]
	neterogeneity.	Tau -	0.00,		<i></i>	- 2 (1	- 0.00	j, 1 − 0 /8		JOL Z - 12.00 (1	- 0.00001)
	Trandala	nhur									
	Trendelei	indur	9					-	3 0	+8	
	Hwang 2013-T	18	3	25	22	4	25	6.0%			-4.00 [-5.96, -2.04]
	Yoo 2014	19.9	3.8	33	23.5	4.3	33	6.0%			-3.60 [-5.56, -1.64]
	Park 2016	17.7	3.2	21	21.8	4.4	21	4.2%			-4.10 [-6.43, -1.77]
	Kaur 2018	15.5	0.9	30	19.8	1.2	30	79.4%	-		-4.30 [-4.84, -3.76]
	Seo 2018	20.39	3.09	23	24.56	4.64	23	4.4%			-4.17 [-6.45, -1.89]
E:	Hotorogonoitu	Tou2 =	0.00	132	E2 df-	- 4 (D	- 0.07	100%		ot: 7 - 17.21 (D	-4.23 [-4.70, -3.75]
Si.	Helefogeneily.	Tau	0.00,	Cn⊧ – t).55, ui -	-4(P	- 0.97), I [_] − 0 %	rest for overall elle	CL Z = 17.31 (P)	< 0.00001)
6	Lateral de	ecubi	tus					-4	+ 0	+4	
	Yamada 2016	16.6	4	14	17.2	3.9	14	16.8%			-0.60 [-3.53, 2.33]
	Kim 2019	13.26	2.65	23	15.48	1.83	23	83.2%			-2.22 [-3.54, -0.90]
	Total (95%Cl)			37			37	100%			-1.95 [-3.15, -0.75]
	Heterogeneity:	Tau ² =	0.00;	Chi² = ().98, df :	= 1 (P	= 0.32); I² = 0%	Test for overall effe	ect: Z = 3.18 (P =	= 0.001)
	Deep										
8	Pro	ne						-1	6 0	+6	5
	Sugata 2012	21.9		5 12	2 24.8	3.4	12	38.7%		-	-2.90 [-6.32, 0.52]
	Mirkheshti 201	17 17.2	4.9	9 30) 18	5.8	30	61.3%			-0.80 [-3.52, 1.92]
	Total (95%CI)			42	2		42	100%			-1.61 [-3.74, 0.52]
	Heterogeneity	: lau ² =	= 0.00;	Chi ² =	u.89, df	= 1 (F	- = 0.35	o); I² = 0%	l est for overall ef	rect: Z = 1.49 (P	= 0.14)

Fig. 3. Forest plot of intraocular pressure at different timings.

reverse Trendelenburg positioning, two (n = 74) after LDP, and four (n = 189) after the resolution of pneumoperitoneum. After intubation, MAP in the propofol-based TIVA group was significantly lower than that in the VA group (WMD, -6.61; 95% CI, -10.56 to -2.66; P < 0.01). However, after pneumoperitoneum, MAP was significantly higher in the propofol-based TIVA group (WMD, 0.81; 95% CI, 0.01 to 1.60; P = 0.05). There was no significant heterogeneity

across studies after intubation and pneumoperitoneum (Chi² = 4.92, P = 0.55, I² = 0%; Chi² = 0.75, P = 0.86, I² = 0%). The pooled effect estimate showed no significant intergroup difference in IOP after induction (WMD, 0.08; 95% CI, -1.42 to 1.59; P = 0.91), after Trendelenburg positioning (WMD, 0.37; 95% CI, -2.30 to 3.03; P = 0.79), after reverse Trendelenburg positioning (WMD, -2.34; 95% CI, -9.00 to 4.32; P = 0.49), after LDP (WMD, -2.62;

	Study ID	Prop Mear	o <mark>fol</mark>	TIVA Total	V Mean	olatil _{SD}	e Total	Weight -	Favor Propofol -TIVA 10 ← C	lean Differen ^{Favor} Volatile	ce (9 <u>4</u> +10	5% CI)
Ę	Yamada 2016	50.4	10.1	14	52.4	10.9	14	49.2%				-2.00 [-9.78, 5.78]
ctic	Kim 2019 1	03.13	14.99	23	107.87	11.24	23	50.8%	← ■			-4.74 [-12.40, 2.92]
que	Total (95%Cl)		37			37	100%		-		-3.39 [-8.85, 2.07]
Ē	Heterogeneity	: Tau² =	= 0.00;	Chi² = 0	.24, df =	1 (P =	0.62); I	² = 0% Te	est for overall effec	et: Z = 1.22 (P =	0.22)	
								-	10	0	+10	
2	Yamada 2016	6 46.3	13.1	14	52.5	13.3	14	38.0%	< ─■			-6.20 [-15.98, 3.58]
eral	Kim 2019	70.13	10.34	23	68.52	11.39	23	62.0%				1.61 [-4.68, 7.90]
ate	Total (95%Cl)		37	0		37	100%				-1.36 [-8.79, 6.07]
ď	Heterogeneity	/: Tau² :	= 12.91	; Chi² =	1.73, df	= 1 (F	9 = 0.19)	; l² = 42%	Test for overall e	effect: Z = 0.36	(P = 0	.72)

Fig. 4. Forest plot of ocular perfusion pressure at different timings.

										N	Aean Differen	ce (95% Cl)
			Prop	ofol -	TIVA	V	olatil	le		Favor	Favor	
		Study ID	Mean	SD	Total	Mean	SD	Total	Weight	Propofol -TIVA	Volatile	. 10
		Sugata 2012	37	5	12	34	4	12	9.9%			3.00 [-0.62, 6.62]
2		Yoo 2014	3.3	2.7	33	33.1	3.2	33	38.6%	_	-	0.20 [-1.23, 1.63]
		Yamada 2016	31	6	14	27	6	14	6.9%			4.00 [-0.44, 8.44]
Ē	י ג ג	Kaur 2018	30.8	2	30	30.4	2.8	30	44.7%	-	-	0.40 [-0.83, 1.63]
2	2	Total (95%CI)			89			89	100%		•	0.83 [-0.39, 2.05]
		Heterogeneity:	Tau ² =	0.47;	Chi² =	4.33, df	= 3 (P	= 0.23); I² = 31%	Test for overall e	effect: Z = 1.33	(P = 0.18)
									-:	8	0 .	+8
		Asuman 2013	35	0.4	14	35	2.4	18	22.6%	-	-	0.00 [-1.13, 1.13]
2	5	Yamada 2016	34	6	14	32	6	14	1.5%			2.00 [-2.44, 6.44]
ati.	5	Seo 2018	33	3.14	23	34	1.93	23	12.7%		-	-1.00 [-2.51, 0.51]
4	2	Kim 2019	33.39	1.12	23	33.26	1.21	23	63.3%	-	-	0.13 [-0.54, 0.80]
t		Total (95%CI)			74			78	100%			-0.02 [-0.55, 0.52]
		Heterogeneity:	Tau ² =	0.00;	Chi² = 2	2.61, df	= 3 (P	= 0.46)	; I² = 0%	Test for overall e	ffect: Z = 0.06 (P = 0.96)
										4	0 .	+4
	_	Asuman 2013	35	4	14	36	4	18	7.0%			-1.00 [-3.79, 1.79]
6	nn	Yoo 2014	34.5	4.6	33	35	5.5	33	9.1%			-0.50 [-2.95, 1.95]
Ē	ne	Seo 2018	32.13	1.71	23	32.52	2.04	23	46.1%			-0.39 [-1.48, 0.70]
Jer	ito	Kaur 2018	37	1.7	30	37.5	2.9	30	37.7%			-0.50 [-1.70, 0.70]
Ъ	Per	Total (95%CI)			100			104	100%	-		-0.48 [-1.22, 0.25]
	<u>0</u>	Heterogeneity:	Tau² =	0.00;	Chi² = (0.16, df	= 3 (P	= 0.98)	; I² = 0%	Test for overall e	ffect: Z = 1.28 (P = 0.20)
		- 11										
		Irendeler	nbur	g					-1	б	0	+6
		Yoo 2014	40.8	7.6	33	40	6.1	33	3.9%			0.80 [-2.52, 4.12]
		Kaur 2018	40.5	1.7	30	41.1	2.6	30	35.3%		+	-0.60 [-1.71, 0.51]
	_	Seo 2018	32.96	1.42	23	33.22	1.51	23	60.8%	-	-	-0.26 [-1.11, 0.59]
Ż	5	Total (95%CI)			86			86	100%			-0.34 [-1.00, 0.32]
E		Heterogeneity:	Tau ² =	0.00;	Chi ² = (0.70, df	= 2 (P	= 0.71)	; I² = 0%	Test for overall e	effect: Z = 1.00	(P = 0.32)
č	2											
		Lateral de	ecub	itus						8	0	+8
		Yamada 2016	32	6	14	36	3	14	36.7%			-4.00 [-7.51, -0.49]
		Kim 2019 3	30.48	0.79	23	31.04	1.07	23	63.3%	-	ŀ	-0.56 [-1.10, -0.02]
		Total (95%CI)			37			37	100%			-1.82 [-5.07, 1.43]
		Heterogeneity:	Tau ² =	4.27;	Chi² =	3.60, df	= 1 (P	= 0.06); I² = 72%			

Fig. 5. Forest plot of end-tidal CO_2 at different timings.

									Mean Difference (95% Cl)	_
		Propo	ofol -	TIVA	Ve	olati	e		Favor Favor	
	Study ID	Mean	SD	Total	Mean	SD	Total	Weight -	$3 \longleftarrow 0 \longrightarrow +3$	
	Hwang 2013-R	T 15	2	25	16	3	25	8.1%	-1.00 [-2.41, 0.41]	
no	Hwang 2013-T	15	2	25	15	2	25	13.1%	0.00 [-1.11, 1.11]	
Ŀ.	Park 2016	14.9	2.4	21	14.8	1.9	21	9.4%	0.10 [-1.21, 1.41]	
q	Kaur 2018	13.7	0.9	30	13.5	1	30	69.5%	0.20 [-0.28, 0.68]	
2	Total (95%CI)			101			101	100%	0.07 [-0.33, 0.47]	
	Heterogeneity:	Tau ² =	0.00;	Chi² = 2	.50, df =	= 3 (P	= 0.48); I ² = 0% [·]	Test for overall effect: Z = 0.33 (P = 0.74)	
								-3	3 0 +3	
Ę	Seo 2018	13.57	2.63	23	14.52	3.01	23	39.8%	-0.95 [-2.58, 0.68]	
atic	Kim 2019	14.78	2.04	23	16.35	2.53	23	60.2%	-1.57 [-2.90, -0.24]	
tub	Total (95%CI)			46			46	100%	-1.32 [-2.35, -0.29]	
Ē	Heterogeneity:	Tau ² =	0.00; (Chi² = 0.	33, df =	= 1 (P	= 0.56)	; I² = 0%	Test for overall effect: Z = 2.52 (P = 0.01)	
								-2	2 0 +2	
<u>, E</u>	Kaur 2018	18.9	1.4	30	19	2	30	80.5%	-0.10 [-0.97, 0.77]	
neu	Seo 2018	20.22	3.3	23	20.48	2.83	23	19.5%	-0.26 [-2.04, 1.52]	
neu rito	Total (95%Cl)			53			53	100%	-0.13 [-0.92, 0.65]	
Pe P	Heterogeneity:	Tau² =	0.00; (Chi² = 0.	03, df =	= 1 (P	= 0.87)	; I ² = 0% T	Γest for overall effect: Z = 0.33 (P = 0.74)	
								-4	4 0 +4	
bır	Hwang 2013-T	24		4 25	23	3 3	25	20.1%	1.00 [-0.96, 2.96]	$ \prec$
Jdr	Park 2016	23.8	3.	9 21	22.5	5 2.6	21	19.6%	1.30 [-0.70, 3.30]	
ler	Kaur 2018	21.6	1.:	3 30	21.9) 2	30	37.4%	-0.30 [-1.15, 0.55]	
Jde	Seo 2018	23.09	3.32	2 23	24.83	2.7	23	22.8%	-1.74 [-3.49, 0.01]	
rec	Total (95%CI)			99			99	100%	-0.05 [-1.22, 1.11]	
	Heterogeneity:	Tau ² =	0.75;	Chi² = 6	.62, df :	= 3 (P	= 0.09); I ² = 55%	Test for overall effect: Z = 0.09 (P = 0.93)	

Fig. 6. Forest plot of peak inspiratory pressure at different timings.

95% CI, -9.07 to 3.83; P = 0.43), and after resolution of pneumoperitoneum (WMD, 0.41; 95% CI, -3.03 to 3.86; P = 0.82) (Fig. 7).

In the TSA of intubation, the cumulative Z-curve reached the estimated RIS and surpassed the traditional boundary for statistical significance (TSA-adjusted CI, -10.99 to -2.12; calculated Cohen's d, -0.414; and NNT, 7.44). In the TSA of pneumoperitoneum, the cumulative Z-curve surpassed the traditional boundary for statistical significance but did not reach the estimated RIS and did not surpass the lower sequential monitoring boundary for the adjusted significance threshold (TSA-adjusted CI, -0.39 to 2.01; calculated Cohen's d, 0.067; and NNT, 51.86). In the TSA of LDP and reverse Trendelenburg positioning, the cumulative Z-curve did not reach the estimated RIS and did not surpass the sequential monitoring boundary for the adjusted significance threshold. In the TSA of induction, Trendelenburg positioning and pneumoperitoneum resolution, the sequential monitoring boundary for the adjusted significance threshold was ignored due to too little information used (0.26%, 0.94%, and 1.53%) (Suppl. Fig. S7).

In the outcome of MAP after induction, propofol was used for induction in the propofol-TIVA group in all studies, while thiopental was used in five studies [32–34,38,39] and propofol in four [28,30,35,41] for induction in the VA group. In the subgroup analysis, MAP after induction was not significantly different between the propofol-TIVA group and the VA group with thiopental (WMD, -1.02; 95% CI, -4.19 to 2.15; P = 0.53) or propofol (WMD, 0.55; 95% CI, -1.49 to 2.60; P = 0.60) as the induction agent (Suppl. Fig. S8). In the outcome of MAP after intubation, propofol was used for induction in the propofol-TIVA group in all studies,

whereas thiopental was used in five studies [29,31,38,39,42] and propofol in two [35,43] for induction in the VA group. The subgroup analysis showed that MAP after intubation in the propofol-TIVA group was significantly lower than that in the VA group with thiopental as the induction agent (WMD, -7.90; 95% CI, -12.77 to -3.02; P < 0.01). However, MAP was not significantly different between the propofol-TIVA group and the VA group with propofol as the induction agent (WMD, -4.08; 95% CI, -10.87 to 2.72; P = 0.24) (Suppl. Fig. S9).

Influence analysis

An influence analysis was conducted for each outcome except those including only two studies. The results of the influence analysis for all outcomes showed that the re-calculated pooled estimates after the omission of one study at a time were within the 95% Cl of the pooled estimate of all studies, indicating the robustness of the results (Suppl. Figs. S10-14).

Discussion

Endotracheal intubation is associated with a marked increase in IOP, likely attributable to the increase in MAP and subsequent increase in the choroidal blood flow [44]. Propofol-based TIVA has been shown to result in lower heart rate and MAP after induction and intubation than sevoflurane and isoflurane in a previous study [45], thereby leading to a lower IOP. Different induction agents may also play an important role in IOP after intubation.

									M	lean Differen	ice (95% CI)
		Prop	ofol -	TIVA	Vo	olatil	e		Favor	Favor	
	Study ID	<u>.</u>	CD	T	-	CD	Tettel	M	Propofol -TIVA	Volatile	- 22
	Study ID	Mean	SD	lotal	Mean	SD	Total	Weight -	20 - 0		+20
	Guedes 1988	90.83	17.05	15	98.57	13.74	15	1.8%			-7.74 [-18.82, 3.34]
	Polarz 1995	85	19	20	92	20	20	1.6%	· · · · ·		-7.00 [-19.09, 5.09]
	Schafer 2002	76	20	20	73	15	20	1.9%			3.00 [-7.96, 13.96]
	Son 2005	76.5	9.9	15	73.4	7.1	16	6.1%		·	3.10 [-3.00, 9.20]
LO LO	Sugata 2012	78	15	12	81	13	12	1.8%			-3.00 [-14.23, 8.23]
E	Hwang 2013-F	RT 71	13	25	75	13	25	4.4%			-4.00 [-11.21, 3.21]
du	Hwang 2013-T	72	13	25	72	12	25	4.7%			0.00 [-6.94, 6.94]
<u> </u>	Yoo 2014	83.9	13.2	33	78.6	12.6	33	5.9%	-		5.30 [-0.93, 11.53]
	Park 2016	72	13.2	21	71.8	11.7	21	4.0%			0.20 [-7.34, 7.74]
	Kaur 2018	82.3	4.4	30	82.3	2.6	30	67.9%		F. Contraction	0.00 [-1.83, 1.83]
	Total (95%Cl)			216			217	100%			0.08 [-1.42, 1.59]
	Heterogeneity	: Tau² =	0.00;	Chi² = 8	3.67, df =	= 9 (P =	= 0.47);	l² = 0%	Test for overall ef	fect: Z = 0.11 (P = 0.91)
								-3	30 () .	+30
	Guedes 1988	102.83	17.54	15	101.7	17.8	3 15	9.8%		•	1.13 [-11.52, 13.78]
	Polarz 1995	86	20	20	95	22	20	9.2%			-9.00 [-22.03, 4.03]
	Schafer 2002	76	18	20	79	14	20	15.6%			-3.00 [-12.99, 6.99]
io	Asuman 2013	100	19	14	105	15	18	10.6%			-5.00 [-17.13, 7.13]
bat	Yamada 2016	70	12	14	75	13	14	18.2%			-5.00 [-14.27, 4.27]
It	Seo 2018	116.3	17.42	23	131.78	20.64	23	12.8%	·		-15.48 [-26.52, -4.44]
	Kim 2019 1	18.52	15.99	23	126.91	11.68	23	23.8%			-8.39 [-16.48, -0.30]
	Total (95%CI)			129			133	100%	-		-6.61 [-10.56, -2.66]
	Heterogeneity:	: Tau² =	0.00; 0	Chi² = 4	.92, df =	6 (P =	0.55); l ²	e = 0% Te	est for overall effect	t: Z = 3.28 (P =	0.001)
								_	6	n	+6
	Asuman 2013	107	21	14	102	19	18	0.3%	<u> </u>		→ 5.00 [-9.07, 19.07]
_	Yoo 2014	98.4	14 4	33	96.5	16.2	33	1.2%			→ 1.90 [-5.50, 9.30]
-ou	Kaur 2018	96.8	1.2	30	96	1.9	30	97.9%		-	0.80 [-0.00, 1.60]
E E	0 0040			00	104 50	10.6	23	0.6%			2 12 [12 16 7 00]
te	Seo 2018	102.39	14.78	23	104.52	19.0	20	0.070			-2.13[-12.10, 7.90]
Pne	Seo 2018 Total (95%Cl))	14.78	100	104.52	19.0	104	100%		•	0.81 [0.01, 1.60]
Pne	Total (95%Cl) Heterogeneity	102.39) : Tau² =	14.78	23 100 Chi² = 0	104.52).75, df =	3 (P =	104 = 0.86);	0.8% 100% I² = 0% T	est for overall effe	ct: Z = 1.99 (P	0.81 [0.01, 1.60]
Pne	Total (95%Cl) Heterogeneity	102.39) : Tau² =	0.00;	23 100 Chi² = 0	0.75, df =	3 (P =	104 = 0.86);	100% 1 ² = 0% T	est for overall effe	ct: Z = 1.99 (P	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05)
Pne	Seo 2018 Total (95%Cl) Heterogeneity Son 2005	102.39) : Tau² = 95.7	14.78 0.00; ¹ 9.4	23 100 Chi ² = 0 15	91.6	3 (P =	104 = 0.86); 16	100% 1 ² = 0% T - 10.0%	est for overall effe	ct: Z = 1.99 (P	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 4.10 [-3.39, 11.59]
g Pne	Seo 2018 Total (95%Cl) Heterogeneity Son 2005 Hwang 2013-1	102.39 : Tau ² = 95.7	14.78 0.00; • 9.4	23 100 Chi ² = 0 15 25	0.75, df = 91.6 89	19.8 3 (P = 11.8 10	104 = 0.86); 16	0.8% 100% I ² = 0% T 	est for overall effe	ct: Z = 1.99 (P	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76]
ourg Pne	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-1 Yoo 2014	102.39 : Tau ² = 95.7 F 88 90.6	14.78 0.00; 1 9.4 15 9.4	23 100 Chi ² = 0 15 25 33	104.52 0.75, df = 91.6 89 93.5	19.0 3 (P = 11.8 10 16.3	104 = 0.86); 16 15 33	0.0% 100% 1 ² = 0% T - 10.0% 9.4% 12.6%	iest for overall effe	ct: Z = 1.99 (P	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52]
enburg Pne	Seo 2018 Total (95%Cl) Heterogeneity Son 2005 Hwang 2013-1 Yoo 2014 Park 2016	102.39 : Tau ² = 95.7 F 88 90.6	14.78 0.00; 9.4 15 9.4 14 5	23 100 Chi ² = 0 15 25 33	91.6 93.5 89	19.0 3 (P = 11.8 10 16.3 9.8	104 = 0.86); 16 15 33 21	0.0% 100% 1 ² = 0% T - 10.0% 9.4% 12.6% 10.0%	est for overall effe	ct: Z = 1.99 (P	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09]
lelenburg	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-1 Yoo 2014 Park 2016 Seo 2018	102.39 : Tau ² = 95.7 Г 88 90.6 88 105 78	14.78 0.00; 9.4 15 9.4 14.5 9.67	23 100 Chi ² = 0 15 25 33 5 21	91.6 93.5 93.5 89.4 98.74	19.0 3 (P = 11.8 10 16.3 9.8 11 91	104 = 0.86); 16 15 33 21 23	0.0% 100% 1 ² = 0% T 	est for overall effe	ct: Z = 1.99 (P 0	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] 7.04 [0.77, 13.31]
ndelenburg Pne	Seo 2018 Total (95%C) Heterogeneity Son 2005 Hwang 2013-T Yoo 2014 Park 2016 Seo 2018 Kaur 2018	102.39 Tau ² = 95.7 88 90.6 88 105.78 94 2	14.78 0.00; 9.4 15 9.4 14.5 9.67	23 100 Chi ² = C 15 25 33 21 23 23 30	91.6 93.5 93.5 89.4 98.74 95	19.0 3 (P = 11.8 10 16.3 9.8 11.91 1.2	104 = 0.86); 16 15 33 21 23 30	100% 100% 1 ² = 0% T - 10.0% 9.4% 12.6% 10.0% 13.0% 45.0%	est for overall effe	ct: Z = 1.99 (P 0	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03]
Trendelenburg	Seo 2018 Total (95%Cl) Heterogeneity Son 2005 Hwang 2013-T Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%Cl)	102.39) : Tau ² = 95.7 Г 88 90.6 88 105.78 94.2	14.78 0.00; 9.4 15 9.4 14.5 9.67 : 1.8	23 100 Chi ² = C 15 25 33 25 25 25 25 25 23 23 20 21 23 30 247	91.6 93.5 89.4 98.74 95	19.0 3 (P = 11.8 10 16.3 9.8 11.91 1.2	104 = 0.86); 16 15 33 21 23 30 138	100% 12 = 0% T 10.0% 9.4% 12.6% 10.0% 13.0% 45.0%	est for overall effe	ct: Z = 1.99 (P	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03]
Trendelenburg Pne	Seo 2018 Total (95%Cl) Heterogeneity Son 2005 Hwang 2013-T Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%Cl)) : Tau ² = 95.7 F 88 90.6 88 105.78 94.2) : Tau ² =	14.78 0.00; 9.4 15 9.4 14.5 9.67 : 1.8	23 100 Chi ² = C 15 25 33 21 23 30 21 23 30 147 22	91.6 93.5 89.4 98.74 98. df = 1	13.6 3 (P = 11.8 10 16.3 9.8 11.91 1.2	104 = 0.86); 16 15 33 21 23 30 138 0.16); 18	100% 12 = 0% T 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% = 37% T	est for overall effe	ct: Z = 1.99 (P 0	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] :0.79)
Trendelenburg perit	Seo 2018 Total (95%Cl) Heterogeneity Son 2005 Hwang 2013-T Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%Cl) Heterogeneity	102.39 : Tau ² = 95.7 6 88 90.6 88 105.78 94.2) : Tau ² =	14.78 0.00; 9.4 15 9.4 14.5 9.67 1.8 3.94; 0	23 100 Chi ² = 0 15 25 33 21 23 30 147 Chi ² = 7	91.6 93.5 89.9 93.5 89.4 98.74 95 98, df = 1	13.6 3 (P = 11.8 10 16.3 9.8 11.91 1.2 5 (P =	104 = 0.86); 16 15 33 21 23 30 138 0.16); l ²	100% 100% 1 ² = 0% T 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% = 37% T	est for overall effe	ct: Z = 1.99 (P 0 	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] :0.79) +10
⁹ Trendelenburg	Seo 2018 Total (95%Cl) Heterogeneity Son 2005 Hwang 2013-1 Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%Cl) Heterogeneity Asuman 2013	102.39 : Tau ² = 95.7 F 88 90.6 88 105.78 94.2) : Tau ² =	14.78 0.00; 9.4 15 9.4 14.5 9.67 1.8 3.94; 0	23 100 Chi ² = C 15 25 33 21 23 30 147 Chi ² = 7. 1 1	91.6 91.6 89 93.5 89.4 98.74 95 98, df = 1	19.6 3 (P = 11.8 10 16.3 9.8 11.91 1.2 5 (P =	104 = 0.86); 16 15 33 21 23 30 138 0.16); l ²	100% 100% 1 ² = 0% T 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% = 37% T - - - - - - - - - - - - -	est for overall effe	ct: Z = 1.99 (P 0 t: Z = 0.27 (P = 0	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] : 0.79) +10 → 2.00 [-7.37, 11.37]
Trendelenburg	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-1 Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Asuman 2013 Hwang 2013-1	102.39 : Tau ² = 95.7 F 88 90.6 88 105.78 94.2) : Tau ² = 3 10: RT 8	9.4 9.4 15 9.4 14.5 9.67 : 1.8 3.94; C 5 1	23 100 Chi ² = C 15 25 33 21 23 30 147 Chi ² = 7. 1 1 4 2	91.6 89 93.5 89.4 98.74 95 98, df = 1 98, df = 1 4 103	3 (P = 11.8 10 16.3 9.8 11.91 1.2 5 (P =	104 = 0.86); 16 15 33 21 23 30 138 0.16); 1 ² 18 25	100% 100% 12 = 0% T - 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% = 37% T - - - - - - - - - - - - -	est for overall effe	ct: Z = 1.99 (P 0 	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.79) +10 → 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52]
everse detemburg Trendelenburg Pne perit	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-1 Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Asuman 2013 Hwang 2013-1 Total (95%CI)	102.39 : Tau ² = 95.7 88 90.6 88 105.78 94.2) : Tau ² = 3 10! RT 8:	14.78 0.00; + 9.4 15 9.4 14.5 9.67 : 1.8 3.94; C 5 1 5 1	23 100 Chi ² = C 15 25 33 21 23 30 147 Chi ² = 7 1 1 4 2 39	91.6 89 93.5 89.4 98.74 95 98, df = 1 98, df = 1 4 103 5 90	19.8 (P = 11.8 10 16.3 9.8 11.91 1.2 5 (P = 5 16) 9	23 104 = 0.86); 16 15 33 21 23 30 138 0.16); ² 18 25 43	100% 100% 12 = 0% T 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% 38.0% 62.0% 100%	est for overall effe	ct: Z = 1.99 (P 0 	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.79) +10 → 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52] -2.34 [-9.00, 4.32]
Reverse Trendelenburg Pretite	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-1 Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Asuman 2013-1 Total (95%CI) Heterogeneity	102.39 : Tau ² = 95.7 88 90.6 88 105.78 94.2) : Tau ² = 8 103 RT 8:) r Tau ² =	9.4 9.4 15 9.4 14.5 9.67 1.8 3.94; (5 5 1 5 5 1	23 100 102 102 102 102 102 102 102	91.6 91.6 89 93.5 89.4 98.74 95 98, df = 5 4 103 5 90 1 44 df =	3 (P = 11.8 10 16.3 9.8 11.91 1.2 5 (P = 5 (P = 16) 9 9	104 = 0.86); 16 15 33 21 23 30 138 0.16); l ² 18 25 43 = 0.23);	100% 100% 12 = 0% T 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% 38.0% 62.0% 100% 12 = 31%	est for overall effe	ct: Z = 1.99 (P 0 1 1 1 1 1 2 2 2 0 2 1 1 9 1 1 9 1 9 1 1 9 1 9 1 9 1 9 1 9	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.79) +10 → 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52] -2.34 [-9.00, 4.32] P = 0.49)
Reverse Trendelenburg Pne	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-1 Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Total (95%CI) Hwang 2013-1 Total (95%CI)	102.39 Tau ² = 95.7 88 90.6 88 105.78 94.2) Tau ² = 3 104 RT 8:) r: Tau ² =	9.4 9.4 15 9.4 14.5 9.67 5 1 5 1 5 1 5 1 5 1 5 1	23 100 Chi² = C 15 25 33 3 21 23 3 3 3 147 147 1 1 1 1 1 4 29 30 147 15 15 15 15 15 15 15 15 15 15	91.6 89 93.5 89.4 98.74 95 98, df = 1 4 103 5 90	3 (P = 11.8 10 16.3 9.8 11.91 1.2 5 (P = 16 5 (P = 16) 9 5 (P =	104 104 16 15 33 21 23 30 138 23 30 138 18 25 43 25 43	100% 100% 12 = 0% T 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% 138.0% 62.0% 100% 12 = 31%	est for overall effe	ct: Z = 1.99 (P 0 t: Z = 0.27 (P = 0 ffect: Z = 0.69 (-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.79) +10 → 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52] -2.34 [-9.00, 4.32] P = 0.49) +10
Reverse Trendelenburg Pne	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-1 Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Asuman 2013-1 Total (95%CI) Heterogeneity	102.39 : Tau ² = 95.7 F 88 90.6 88 90.6 88 94.2) : Tau ² = 3 10: ; Tau ² = 3 10: ; 7 Tau ² = 3 10: ; 7 Tau ² =	9.4 9.4 15 9.4 14.5 9.67 5 1 5 1 5 1 5 1 5 1	23 100 Chi ² = C 15 25 33 3 21 23 3 3 0 147 1 1 1 1 1 4 2 39 Chi ² = 7 14	0.75, df = 91.6 89 93.5 89.4 98.74 95 98, df = 98, df = 1.44, df =	13.3 (P = 11.8 10 16.3 9.8 11.91 1.2 5 (P = 5 (P = 5 16) 9 5 (P =	203 104 106 15 33 21 23 30 138 23 30 138 25 43 25 43 14	100% 100% 12 = 0% T - 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% = 37% T - 38.0% 62.0% 100% 12 = 31% - - - - - - - - - - - - -	est for overall effe	ct: Z = 1.99 (P 0) t: Z = 0.27 (P = 0) (Fect: Z = 0.69 (0 0	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.79) +10 → 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52] -2.34 [-9.00, 4.32] P = 0.49) +10
al Reverse Trendelenburg Pne itus	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-1 Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Asuman 2013-1 Total (95%CI) Heterogeneity Yamada 2016 Kim 2019	102.39 : Tau ² = 95.7 F 88 90.6 88 90.6 88 94.2) : Tau ² = 3 100 : Tau ² = 3 100 : Tau ² = 71 92.20	9.4 9.4 15 9.4 14.5 9.67 3.94; C 5 1 5 1 5 1 7.53; 14	23 100 100 15 25 33 21 23 30 147 1 1 1 1 1 1 2 39 Chi ² = C 39 20 147 14 20 39 20 147 15 20 20 20 20 20 20 20 20 20 20	91.6 89 93.5 89.4 98.74 95 98, df = 1 98, df = 1 4 1.44, df = 79	13.3 (P = 11.8 10 16.3 9.8 11.91 1.2 5 (P = 16) 9 5 (P = 17 11 08	23 104 106 15 33 21 23 30 138 23 30 138 25 43 25 43 14 23 30 14 25 25 25 25 25 25 25 25 25 25	100% 100% 12 = 0% T - 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% 238.0% 62.0% 100% 12 = 31% - - - - - - - - - - - - -	est for overall effe	ct: Z = 1.99 (P 0) :t: Z = 0.27 (P = 0) ffect: Z = 0.69 (0	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.37 [-2.30, 3.03] 0.79) +10 → 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52] -2.34 [-9.00, 4.32] P = 0.49) +10 -8.00 [-19.54, 3.54] -0.61 [6 73 5 51]
ateral Reverse Trendelenburg Pne cubitus Trendelenburg perit	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-T Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Asuman 2013- Total (95%CI) Heterogeneity Yamada 2016 Kim 2019 Total (95%CI)	102.39 : Tau ² = 95.7 F 88 90.6 88 90.6 88 94.2) : Tau ² = 3 10 ² : Tau ² = 71 83.39	9.4 9.4 15 9.4 14.5 9.67 5 1 5 1 5 1 5 1 5 1 5 1 14 10.07	23 100 Chi ² = C 15 25 33 21 23 300 147 1 1 1 1 1 4 29 Chi ² = 7 14 23 37	91.6 89 93.5 89.4 98.74 95 98, df = 1 4 103 5 90 1.44, df = 79 84	11.8 11.8 10 16.3 9.8 11.91 1.2 5 (P = 16 16 9 5 (P = 17 11.08	23 104 16 15 33 21 23 30 138 23 30 138 25 43 25 43 14 23 37	100% 100% 12 = 0% T - 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% 238.0% 62.0% 100% 12 = 31% - 27.2% 100%	est for overall effe	ct: Z = 1.99 (P 0 ::: Z = 0.27 (P = 0 ::: Z = 0.69 (0 0	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.37 [-2.30, 3.03] 0.37 [-2.30, 3.03] 0.79) +10 → 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52] -2.34 [-9.00, 4.32] P = 0.49) +10 -8.00 [-19.54, 3.54] -0.61 [-6.73, 5.51] -2.62 [-9.07, 3.83]
Lateral Reverse Trendelenburg Pne	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-T Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Yamada 2016 Kim 2019 Total (95%CI)	102.39 : Tau ² = 95.7 F 88 90.6 88 90.6 88 94.2) : Tau ² = 71 83.39 71 83.39 71 71 71 71 71 71 71 71 71 70 70 70 70 70 70 70 70 70 70	14.78 0.00; + 9.4 15 9.4 14.5 9.67 1.8 3.94; (5 1 5 1 5 1 5 1 14 10.07 5 11.0	23 100 Chi ² = C 15 25 33 21 23 300 147 14 23 39 Chi ² = 7 14 23 37 Chi ² = 1 24 39 29 Chi ² = 7 14 23 37 25 25 25 25 25 25 25 25 25 25	91.6 89 93.5 89.4 98.74 95 98, df = 1 4 103 5 90 1.44, df = 79 84	11.8 11.8 10 16.3 9.8 11.91 1.2 5 (P = 16 16 9 5 (P = 17 11.08 1 (P =	104 104 16 15 16 15 16 15 21 13 30 138 25 43 25 43 14 23 14 23 37 24 23 24 23 24 23 24 23 24 23 24 24 25 24 24 25 24 25 26 26 26 26 26 26 26 26 26 26	100% 100% 12 = 0% T - 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% = 37% T - 38.0% 62.0% 100% 12 = 31% - - - - - - - - - - - - -	est for overall effer	ct: Z = 1.99 (P 0 ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.37 [-2.30, 3.03] 0.37 [-2.30, 3.03] 0.79) +10 → 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52] -2.34 [-9.00, 4.32] P = 0.49) +10 -8.00 [-19.54, 3.54] -0.61 [-6.73, 5.51] -2.62 [-9.07, 3.83]
Lateral Reverse Trendelenburg Pne Portug	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-T Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Yamada 2016 Kim 2019 Total (95%CI) Heterogeneity	102.39 : Tau ² = 95.7 88 90.6 88 90.6 88 94.2) : Tau ² = 71 83.39) Tau ² = 71 83.39	14.78 0.00; + 9.4 15 9.4 14.5 9.67 1.8 3.94; (5 1 5 1 5 1 5 1 7.53; 14 10.07 5.11; (0.07 11; (12) 14; (14) 14; (14) 15; (14) 14; (14) 15; (14) 15; (14) 15; (14) 15; (14) 15; (14) 15; (14) 15; (14) 15; (14) 14; (15) 14; (14) 15; (15; (15) 15; (15; (15) 15; (15; (15) 15; (15; (15) 15; (15; (15) 15; (15; (15; (15) 15; (15; (23 100 Chi ² = C 15 25 33 21 23 300 147 Chi ² = 7 1 1 1 4 2 39 Chi ² = 7 14 37 Chi ² = 7 14 37 Chi ² = 7 14 37 15 15 15 15 15 15 15 15 15 15	91.6 89 93.5 89.4 98.74 95 98, df = 1 4 103 5 90 1.44, df = 79 84 23, df = 1	11.8 11.8 10 16.3 9.8 11.91 1.2 5 (P = 16 16 9 5 (P = 17 11.08 17 11.08 1 (P =	104 104 16 15 16 15 33 21 138 23 300 138 23 300 138 25 43 43 = 0.23); 14 43 37 24 37 30 37 37 37 37 37 37 37 37 37 37	100% 100% 12 = 0% T 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% 238.0% 62.0% 100% 12 = 31% - 27.2% 72.8% 100% 100%	est for overall effective 10 est for overall effective 10 Test for overall effective 10 est for overall effective 10 10 10 10 10 10 10 10 10 10	ct: Z = 1.99 (P 0 t: Z = 0.27 (P = 0 ffect: Z = 0.69 (0 0 t: Z = 0.80 (P =	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.37 [-2.30, 3.03] = 0.79) +10 → 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52] -2.34 [-9.00, 4.32] P = 0.49) +10 -8.00 [-19.54, 3.54] -0.61 [-6.73, 5.51] -2.62 [-9.07, 3.83] = 0.43)
- Lateral Reverse Trendelenburg Pne Portice Decubitus	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-T Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Yamada 2016 Kim 2019 Total (95%CI) Heterogeneity: Son 2005	102.39 : Tau ² = 95.7 F 88 90.6 88 90.6 88 94.2) : Tau ² = 71 83.39) Tau ² = 88 88 83.39	9.4 9.4 15 9.4 14.5 9.67 1.8 3.94; (5 1 5 1 5 1 5 1 7.53; 14 10.07 5.11; (0 6	23 100 Chi ² = C 15 25 33 21 23 300 147 Chi ² = 7 1 1 1 4 2 39 Chi ² = 7 14 23 37 Chi ² = 1.	91.6 89 93.5 89.4 98.74 95 98, df = 1 4 103 5 90 1.44, df = 79 84 23, df = 1 81, 7	11.8 11.8 10 16.3 9.8 11.91 1.2 5 (P = 17 11.08 1 (P =	104 104 16 15 33 21 123 30 138 25 138 25 43 25 43 25 43 25 43 27 14 23 37 24 23 25 24 23 25 24 24 25 25 26 27 27 27 27 27 27 27 27 27 27 27 27 27	100% 100% 12 = 0% T 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% = 37% T - 38.0% 62.0% 100% 12 = 31% - 27.2% 72.8% 100% 100% 100% - - - - - - - - - - - - -	est for overall effective 10 est for overall effective 10 Test for overall effective 10 Te	ct: Z = 1.99 (P 0 1 t: Z = 0.27 (P = 0 1 ffect: Z = 0.69 (0 0 1 t: Z = 0.80 (P = 0	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.37 [-2.30, 3.03] = 0.79) +10 → 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52] -2.34 [-9.00, 4.32] P = 0.49) +10 -8.00 [-19.54, 3.54] -0.61 [-6.73, 5.51] -2.62 [-9.07, 3.83] = 0.43) +15 -6.60 [0 36, 12, 84]
mo- Lateral Reverse Trendelenburg Pne Decubitus Trendelenburg Pne	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-T Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Yamada 2016 Kim 2019 Total (95%CI) Heterogeneity Son 2005 Acumos 2017	102.39 : Tau ² = 95.7 F 88 90.6 88 90.6 88 94.2) : Tau ² = 71 83.39) Tau ² = 88.3 102 102 102 102 102 102 102 102	9.4 9.4 15 9.4 14.5 9.67 5 1 5 1 5 1 5 1 5 1 10.07 5.11; C 9.6 17	23 100 Chi ² = C 15 25 33 21 23 300 147 Chi ² = 7 1 1 1 4 2 39 Chi ² = 7 14 23 37 Chi ² = 1. 15 14 15 14 15 14 15 14 15 15 15 15 15 15 15 15 15 15	0.75, df = 91.6 89 93.5 89.4 98.74 95 98, df = 4 103 5 90 1.44, df = 79 84 23, df = 1 81.7	11.8 10 16.3 9.8 11.91 1.2 5 (P = 16 5 (P = 17 11.08 1 (P = 8 14	104 104 16 15 33 21 123 30 138 25 138 25 43 25 43 25 43 25 43 25 43 27 14 23 37 0.27); l ²	100% 100% 12 = 0% 1 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% 38.0% 62.0% 100% 12 38.0% 62.0% 100% 12 38.0% 62.0% 100% 12 38.0% 62.0% 100% 12 38.0% 62.0% 100% 12 31.0% 27.2% 72.8% 100% = 19% 19.1%	est for overall effective 10 est for overall effective 10 Test for overall effective 10 Te	ct: Z = 1.99 (P 0) :t: Z = 0.27 (P = 0) :ffect: Z = 0.69 (0 0) :t: Z = 0.80 (P = 0	 -2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.79) +10 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52] -2.34 [-9.00, 4.32] P = 0.49) +10 -8.00 [-19.54, 3.54] -0.61 [-6.73, 5.51] -2.62 [-9.07, 3.83] 0.43) +15 6.60 [0.36, 12.84] 2.00 [-9.01, 13.01]
neumo- Lateral Reverse Trendelenburg Pne pum Decubitus Trendelenburg Pretit	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-1 Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Yamada 2016 Kim 2019 Total (95%CI) Heterogeneity Son 2005 Asuman 2013	102.39 : Tau ² = 95.7 88 90.6 88 90.6 88 90.6 88 94.2 94.2 94.2 9 : Tau ² = 102 71 83.39) Tau ² = 88.3 88.3 9 202 202 202 202 202 202 202	9.4 9.4 15 9.4 14.5 9.67 1.8 3.94; (5 1 5 1 7.53; 14 10.07 5.11; (9.6 7.511; (9.6 17 10.5	23 100 Chi ² = C 15 25 33 21 23 30 147 14 23 30 147 1 1 1 1 1 4 2 39 Chi ² = 7 30 Chi ² = 7 30 147 15 15 15 15 15 15 15 15 15 15	104.32 9.75, df = 91.6 89 93.5 89.4 98.74 95 98, df = 4 103 5 90 1.44, df = 79 84 23, df = - 81.7 100	11.8 11.8 10 16.3 9.8 11.91 1.2 5 (P = 16 17 11.08 1 (P = 8 14 14 11 6	104 104 104 16 15 33 21 13 23 30 138 25 43 25 43 25 43 25 43 14 23 37 0.27); l ² 16 18 27 19 10 10 10 10 10 10 10 10 10 10	100% 100% 12 = 0% T 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% = 37% T 38.0% 62.0% 100% 12 = 31% - 27.2% 72.8% 100% = 31% - 27.2% 100% - 27.2% - 27.2% - 27.2% - 27.2% - 27.2% - - - - - - - - - - - - -	est for overall effective 10 est for overall effective 10 Test for overall effective 10 est for overall effective 10 est for overall effective 15 est for overall effective	ct: Z = 1.99 (P 0) t: Z = 0.27 (P = 0) (ffect: Z = 0.69 (D 0) (t: Z = 0.80 (P = 0)	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.79) +10 → 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52] -2.34 [-9.00, 4.32] P = 0.49) +10 -8.00 [-19.54, 3.54] -0.61 [-6.73, 5.51] -2.62 [-9.07, 3.83] :0.43) +15 -6.60 [0.36, 12.84] -2.00 [-9.01, 13.01] -2.00 [-9.01, 13.01] -2.00 [-9.01, 13.01]
on Pneumo- Lateral Reverse poneum Decubitus Trendelenburg Pne	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-1 Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Yamada 2016 Kim 2019 Total (95%CI) Heterogeneity Son 2005 Asuman 2013 Yoo 2014	102.39 102.39 102.39 102.39 102.48 105.78 90.6 88 90.6 88 90.6 88 90.6 88 94.2 102.78 94.2 102 102 102 102 102 102 102 10	14.78 9.4 15 9.4 14.5 9.67 9.67 1.8 3.94; C 5 1 1.8 3.94; C 5 1 5 1 5.11; C 9.6 17 10.5 4	23 100 Chi ² = C 15 25 33 21 23 30 147 1 1 1 1 1 4 23 30 147 1 1 1 1 4 23 30 Chi ² = 7 39 Chi ² = 7 1 1 1 1 1 1 1 1 1 1 1 1 1	104.32 9.75, df = 91.6 89 93.5 89.4 98.74 95 98, df = 4 103 5 90 1.44, df = 79 84 23, df = 81.7 100 81.7	11.8 10 16.3 9.8 11.91 1.2 5 (P = 16 17 11.08 1 (P = 8 14 11.6	104 104 105 106 15 16 15 33 21 123 30 138 23 30 138 25 43 25 43 25 43 20 20 20 20 20 20 20 20 20 20	100% 100% 12 = 0% T 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% = 37% T 38.0% 62.0% 100% 12 = 31% - 27.2% 72.8% 100% 12 = 31% - 27.2% 100% 12 = 31% - 23.0% 100% - 23.0% - - - - - - - - - - - - -	est for overall effective 10 est for overall effective 10 Test for overall effective 10 Est for overall effective 10 Est for overall effective 15 Est for overall effective	ct: Z = 1.99 (P 0) t: Z = 0.27 (P = 0) (ffect: Z = 0.69 (0 0) t: Z = 0.80 (P = 0	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.79) +10 → 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52] -2.34 [-9.00, 4.32] P = 0.49) +10 -8.00 [-19.54, 3.54] -0.61 [-6.73, 5.51] -2.62 [-9.07, 3.83] :0.43) +15 -6.60 [0.36, 12.84] -2.90 [-8.24, 2.44] -0.71 [-5.05]
Aution Pneumo- Decubitus Trendelenburg Pne Trendelenburg Pne	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-1 Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Yamada 2016 Kim 2019 Total (95%CI) Heterogeneity Son 2005 Asuman 2013 Yoo 2014 Kaur 2018	102.39 102.39 102.39 102.39 102.39 103.68 105.78 90.6 88 90.6 88 90.6 88 90.6 88 91.7 102 102 102 102 102 102 102 102	14.78 0.00; 4 9.4 15 9.4 14.5 9.67 9.67 1.8 3.94; C 5 1 1.8 3.94; C 5 1 5 1 1.8 3.94; C 5 1 1.8 3.94; C 5 1 1.4 5.11; C 9.6 1.7 1.0 1.7 1.0 1.7 1.6 1.7 1.6 1.7 1.6 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7	23 100 Chi ² = C 15 25 33 21 23 30 147 14 23 30 147 1 1 1 1 1 4 23 30 Chi ² = 7 39 Chi ² = 7 39 Chi ² = 7 10 11 11 12 30 147 147 15 15 15 15 15 15 15 15 15 15	104.32 9.75, df = 91.6 89 93.5 89.4 98.74 95 98, df = 4 103 5 90 1.44, df = 79 84 23, df = 81.7 100 81.1 92.4	11.8 10 16.3 9.8 11.91 1.2 5 (P = 16 17 11.08 1 (P = 8 14 11.6 2.1 	104 104 104 16 15 33 21 13 30 138 23 30 138 25 43 25 43 25 43 25 43 27 14 23 37 0.27); l ² 16 18 33 30 0.27); l ² 16 18 37 18 25 43 37 10 43 37 10 43 10 43 10 43 10 10 10 10 10 10 10 10 10 10	100% 100% 12 = 0% T 10.0% 9.4% 12.6% 10.0% 12.6% 10.0% 13.0% 45.0% 100% = 37% T 38.0% 62.0% 100% 12 = 31% - 27.2% 72.8% 100% = 31% - 27.2% 100% 12.6% - 23.0% 49.7% 100%	est for overall effective 10 est for overall effective 10 Test for overall effective 10 Est for overall effective 10 Est for overall effective 15 Est for overall effective	ct: Z = 1.99 (P 0) t: Z = 0.27 (P = 0) (ffect: Z = 0.69 (D 0) t: Z = 0.80 (P = 0	-2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 → 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] → 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.79) +10 → 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52] -2.34 [-9.00, 4.32] P = 0.49) +10 -8.00 [-19.54, 3.54] -0.61 [-6.73, 5.51] -2.62 [-9.07, 3.83] :0.43) +15 -6.60 [0.36, 12.84] -2.90 [-8.24, 2.44] -0.70 [-1.55, 0.15] 0.41 [-0.73, 5.15] -2.90 [-8.24, 2.44] -0.70 [-1.55, 0.15] 0.41 [-0.73, 5.15] -2.90 [-8.24, 2.44] -0.70 [-1.55, 0.15] 0.41 [-0.73, 5.15] -2.90 [-8.24, 2.44] -0.70 [-1.55, 0.15] -0.71 [-2.50, 2.51] -0.71 [-2.50, 2.51] -0.70 [-1.55, 0.15] -0.71 [-2.50, 2.51] -0.71 [-2.50, 2.51] -0.71 [-2.50, 2.51] -0.71 [-2.50, 2.51] -0.70 [-1.55, 0.15] -0.71 [-2.50, 2.51] -0.71 [-2.50, 2.51] -0.72 [-1.55, 0.15] -0.72 [-1.55, 0.15] -0.71 [-2.50, 2.51] -0.72 [-1.55, 0.15] -0.71 [-2.50, 2.51] -0.72 [-1.55, 0.15] -0.71 [-2.50, 2.51] -0.72 [-1.55, 0.15] -0.71 [-2.50, 2.51] -0.72 [-1.55, 0.15] -0.72 [-1.55, 0.15] -0.73 [-1.55, 0.15] -0.74 [-2.72 [-1.55, 0.15] -0.75 [-1.55, 0.15] -0.75 [-1.55, 0.15] -0.75 [-1.55, 0.15] -0.75 [-1.55 [-1.55] -0.75 [-1.55] -0.75 [-1.55 [-1.55] -0.75 [-1.55] -0.75 [-1.55 [-1.55] -0.75 [-1.55]
Resolution Pneumo- Decubitus Trendelenburg Trendelenburg Pne Decubitus	Seo 2018 Total (95%CI) Heterogeneity Son 2005 Hwang 2013-1 Yoo 2014 Park 2016 Seo 2018 Kaur 2018 Total (95%CI) Heterogeneity Yamada 2016 Kim 2019 Total (95%CI) Heterogeneity Son 2005 Asuman 2013 Yoo 2014 Kaur 2018 Total (95%CI) Heterogeneity Son 2005 Asuman 2013 Yoo 2014 Kaur 2018	102.39 102.39 102.39 102.39 102.39 102.48 105.78 90.6 88 90.6 88 90.6 88 94.2 94.2 94.2 94.2 102 102 102 102 102 102 102 10	14.78 9.4 15 9.4 14.5 9.67 9.67 1.8 3.94; C 5 1 1.8 3.94; C 5 1 5 1 5 1 5 1 14 10.07 5.11; C 9.6 17 10.5 1.1	23 100 Chi ² = C 15 25 33 21 23 30 147 14 23 30 147 14 23 30 Chi ² = 7 11 1 1 1 1 4 23 30 Chi ² = 7 14 37 Chi ² = 10 Chi ² = 7 14 15 15 15 15 15 15 15 15 15 15	104.32 9.75, df = 91.6 89 93.5 89.4 98.74 95 98, df = 4 103 5 90 1.44, df = 79 84 23, df = 81.7 100 81.1 92.4	11.8 10 16.3 9.8 11.91 1.2 5 (P = 16 17 11.08 1 (P = 8 14 11.6 2.1 2 2 (C)	104 104 104 16 15 33 21 13 30 138 23 30 138 23 30 138 25 43 25 43 25 43 25 43 20 14 23 30 188 25 43 21 16 18 25 43 21 16 18 25 43 21 16 18 25 43 21 16 18 25 43 20 18 25 43 21 14 23 30 188 25 43 21 14 23 30 188 25 43 21 14 25 43 21 14 25 43 21 14 25 43 27 16 18 25 43 27 16 16 18 25 43 27 16 16 18 25 43 27 16 16 16 18 25 16 16 17 18 25 16 16 17 18 25 18 18 25 16 16 17 18 25 16 16 17 18 25 16 17 18 25 18 18 25 11 18 25 19 10 11 18 25 11 18 25 19 10 11 18 25 19 10 11 18 25 11 18 25 11 18 25 11 18 25 19 10 10 10 10 10 10 10 10 10 10	100% 100% 12 = 0% T 10.0% 9.4% 12.6% 10.0% 13.0% 45.0% 100% = 37% T 38.0% 62.0% 100% 12 = 31% - 27.2% 72.8% 100% 12 = 31% - 27.2% 100% 12 = 31% - 23.0% 49.7% 100% 100% 100% - - - - - - - - - - - - -	est for overall effective 10 est for overall effective 10 Test for overall effective 10 Test for overall effective 15 Tot for overall effective	ct: Z = 1.99 (P 0) t: Z = 0.27 (P = 0) (ffect: Z = 0.69 (D 0) (t: Z = 0.80 (P = 0)) (ffect: Z = 0.80 (P =	 -2.13 [-12.16, 7.90] 0.81 [0.01, 1.60] = 0.05) +10 4.10 [-3.39, 11.59] -1.00 [-8.76, 6.76] -2.90 [-9.32, 3.52] -1.40 [-8.89, 6.09] 7.04 [0.77, 13.31] -0.80 [-1.57, -0.03] 0.37 [-2.30, 3.03] 0.79) +10 2.00 [-7.37, 11.37] -5.00 [-11.52, 1.52] -2.34 [-9.00, 4.32] P = 0.49) +10 -8.00 [-19.54, 3.54] -0.61 [-6.73, 5.51] -2.62 [-9.07, 3.83] 0.43) +15 6.60 [0.36, 12.84] 2.00 [-9.01, 13.01] -2.90 [-8.24, 2.44] -0.70 [-1.55, 0.15] 0.41 [-3.03, 3.86]

Fig. 7. Forest plot of mean arterial pressure at different timings.

For example, induction by thiopental was associated with higher IOP and blood pressure after induction and intubation than were propofol and etomidate [46–48]. This was compatible with our

subgroup analysis in which we found that IOP and MAP after intubation in the propofol-based TIVA group were significantly lower than that in the VA group with thiopental as the induction agent.

		w	eighted mean difference (95	% CI)		
		8	6 0	ר ₊₆ Favor	Conclusi	ve NNT
	After induction	242		NS)
	After intubation	214	_ _	Propofol-TIV	/A 🗸	7.60
4	After pneumoperitoneum	172	+	Propofol-TIV	/A 🗸	3.24
≌	After Trendelenburg position	264	+	Propofol-TIV	/A 🗸	2.33
	After lateral decubitus position	74	—	Propofol-TIV	/A 🗸	5.57
	After prone position	84		NS		
		-	10 0 +	10		
d d	After intubation	74		NS		
ō	After lateral decubitus position	74		NS		
	A fear to deal to a	-	5 0 .	+6		
	After induction	1/8		NS	_	
်	After intubation	152	+	NS		
L H	After pneumoperitoneum	204		NS	_	
	After Trendelenburg position	172	-	NS		
	After lateral decubitus position	74		NS		
		-	5 O	+6		
	After induction	202	•	NS		
≙	After intubation	92		Propotol-11V	/A 🗸	6.15
	After pneumoperitoneum	106		NS		
	After Trendelenburg position	198		NS		
		-	12 0 +	12		
	After induction	433	+	NS		
	After intubation	262		Propofol-TIV	/A 🗸	7.44
ΡΡ	After pneumoperitoneum	204	•	Volatile		51.86
Σ	After Trendelenburg position	285		NS		
	After reverse Trendelenburg position	82		NS		
	After lateral decubitus position	84		NS		
	After resolution of pneumoperitoneum	189		NS		

Fig. 8. Forest plot of all brief conclusions.

PIP has been shown to increase IOP [49]. The proposed mechanism for the positive correlation between PIP and IOP is that the increased intrathoracic pressure increases the central venous pressure, which in turn increases the episcleral venous pressure and blocks the aqueous humor outflow [9,50], leading to an increased IOP. Propofol and most of the volatile anesthetics are well documented for their bronchodilation property via inhibiting intracellular calcium mobilization [11]. Clinical studies evaluating the effects of propofol and sevoflurane on respiratory mechanics during surgery found no significant difference in PIP [51,52]. However, a recent study demonstrated that the total inspiratory resistance of desflurane is significantly higher than that of sevoflurane and isoflurane at a 1.5 minimum alveolar concentration (MAC) [53]. Therefore, we postulated that the significantly lower PIP after intubation observed in the present study was due to desflurane use in the studies by Seo et al. and Kim et al. [29,42]. Further investigations are required to confirm our theory.

IOP after pneumoperitoneum and Trendelenburg positioning in the propofol-based TIVA group was significantly lower than that in the VA group. The mechanism underlying such a difference was proposed to be the inhibitory effect of propofol on arginine vasopressin (AVP), which increased during laparoscopic surgery [54,55] and Trendelenburg positioning [56]. AVP and its synthetic derivative desmopressin has been shown to increase IOP [57,58]. Propofol inhibits magnocellular neuron excitability in the paraventricular nucleus [59] and supraoptic nucleus [60] via gammaaminobutyric acid(A)-mediated inhibitory currents; therefore, it may attenuate the increase in IOP during pneumoperitoneum and Trendelenburg positioning. On the contrary, the plasma concentration of AVP was not altered by volatile anesthetics [61].

LDP has been shown to increase the IOP of the dependent eye in both anaesthetized patients and healthy subjects [62,63]. The increased IOP in LDP is likely due to the increased episcleral venous pressure and choroidal volume resulting from gravity or a shift of body fluid and jugular vein compression [63]. In the present study, we found that IOP after LDP in the propofol-based TIVA groups was significantly lower than that in the VA group. The mechanism remains unclear. It was postulated that the reducing effect of propofol on IOP was greater than the increasing effect of LDP, but not volatile anesthetics [43]. Further investigations are necessary to explore this finding.

Our study has some limitations. First, the time elapsed between the IOP measurement and intubation was mentioned in some studies [29,31,35-37,39,42] but unclear in others. Moreover, information was unavailable regarding the exhaled concentration of the VA or the MAC after intubation at which the IOP was measured. As a result, it was unclear to what extent the volatile anesthetics affected the IOP and may underestimate the effects of VA after intubation. Second, some of the included studies were not included in the meta-analysis due to insufficient information. As a result, the pooled effect may have been shifted in either direction if these studies had been included in the meta-analysis. Third, our search strategy was based on the primary outcome, i.e., IOP. Although the literature was searched comprehensively, it remains possible that some studies reporting our secondary outcomes were not included. Consequently, the results of the secondary outcomes in this study may be subject to type one or type two errors. Finally, despite attempts to explore possible modulating factors by metaregression to account for the intergroup heterogeneity, we were unable to perform it due to insufficient data.

Conclusions

To the best of our knowledge, this is the first meta-analysis of RCTs to evaluate the effects of propofol-based TIVA and VA on

IOP in patients undergoing surgery. We found that IOP, MAP, and PIP after intubation in the propofol-based TIVA group were significantly lower than that in the VA group. Moreover, the IOP was also significantly lower in the propofol-TIVA group after pneumoperitoneum, Trendelenburg positioning, and LDP (Fig. 8.). Thus, propofol-based TIVA should be the regimen of choice during anesthesia maintenance, especially in at-risk patients.

Funding

This research received no external funding.

Compliance with Ethics Requirements

This article does not contain any studies with human or animal subjects.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jare.2020.02.008.

References

- Klein BE, Klein R, Knudtson MD. Intraocular pressure and systemic blood pressure: longitudinal perspective: the Beaver Dam Eye Study. Br J Ophthalmol 2005;89(3):284–7.
- [2] Murphy DF. Anesthesia and intraocular pressure. Anesth Analg 1985;64 (5):520–30.
- [3] Beulen P, Rotteveel J, de Haan A, Liem D, Mullaart R. Ultrasonographic assessment of congestion of the choroid plexus in relation to carbon dioxide pressure. Eur J Ultrasound 2000;11(1):25–9.
- [4] Murgatroyd H, Bembridge J. Intraocular pressure. BJA. Education 2008;8 (3):100–3.
- [5] Atkinson TM, Giraud GD, Togioka BM, Jones DB, Cigarroa JE. Cardiovascular and ventilatory consequences of laparoscopic surgery. Circulation 2017;135 (7):700–10.
- [6] Kelly DJ, Farrell SM. Physiology and role of intraocular pressure in contemporary anesthesia. Anesth Analg 2018;126(5):1551–62.
- [7] Quigley HA, McKinnon SJ, Zack DJ, Pease ME, Kerrigan-Baumrind LA, Kerrigan DF, et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci 2000;41 (11):3460–6.
- [8] Popa-Cherecheanu A, Schmidl D, Werkmeister RM, Chua J, Garhofer G, Schmetterer L. Regulation of choroidal blood flow during isometric exercise at different levels of intraocular pressure. Invest Ophthalmol Vis Sci 2019;60 (1):176–82.
- [9] Friberg TR, Sanborn G, Weinreb RN. Intraocular and episcleral venous pressure increase during inverted posture. Am J Ophthalmol 1987;103(4):523–6.
- [10] Shen Y, Drum M, Roth S. The prevalence of perioperative visual loss in the United States: a 10-year study from 1996 to 2005 of spinal, orthopedic, cardiac, and general surgery. Anesth Analg 2009;109(5):1534–45.
- [11] Miller RD. Miller's Anesthesia, 8th ed. Philadelphia: PA: Churchill Livingstone/ Elsevier; 2015.
- [12] Artru AA, Momota Y. Trabecular outflow facility and formation rate of aqueous humor during anesthesia with sevoflurane-nitrous oxide or sevofluraneremifentanil in rabbits. Anesth Analg 1999;88(4):781–6.
- [13] Artru AA. Trabecular outflow facility and formation rate of aqueous humor during propofol, nitrous oxide, and halothane anesthesia in rabbits. Anesth Analg 1993;77(3):564–9.
- [14] Cook JH. The effect of suxamethonium on intraocular pressure. Anaesthesia 1981;36(4):359–65.
- [15] Vinik HR. Intraocular pressure changes during rapid sequence induction and intubation: a comparison of rocuronium, atracurium, and succinylcholine. J Clin Anesth 1999;11(2):95–100.
- [16] Sweeney J, Underhill S, Dowd T, Mostafa SM. Modification by fentanyl and alfentanil of the intraocular pressure response to suxamethonium and tracheal intubation. Br J Anaesth 1989;63(6):688–91.

- [17] Domi RQ. A comparison of the effects of sufentanil and fentanyl on intraocular pressure changes due to easy and difficult tracheal intubations. Saudi Med J 2010;31(1):29–31.
- [18] Sator-Katzenschlager SM, Oehmke MJ, Deusch E, Dolezal S, Heinze G, Wedrich A. Effects of remifentanil and fentanyl on intraocular pressure during the maintenance and recovery of anaesthesia in patients undergoing nonophthalmic surgery. Eur J Anaesthesiol 2004;21(2):95–100.
- [19] D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, P. Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097.
- [20] Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366: 14898.
- [21] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177–88.
- [22] Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Med Res Methodol 2017;17(1):39.
- [23] Furukawa TA, Leucht S. How to obtain NNT from Cohen's d: comparison of two methods. PLoS ONE 2011;6(4):e19070.
- [24] Montazeri K, Dehghan A, Akbari S. Increase in intraocular pressure is less with propofol and remifentanil than isoflurane with remifentanil during cataract surgery: A randomized controlled trial. Adv Biomed Res 2015;4:55.
- [25] Mowafi HA, Al-Ghamdi A, Rushood A. Intraocular pressure changes during laparoscopy in patients anesthetized with propofol total intravenous anesthesia versus isoflurane inhaled anesthesia. Anesth Analg 2003;97 (2):471–4. table of contents.
- [26] Sator S, Wildling E, Schabernig C, Akramian J, Zulus E, Winkler M. Desflurane maintains intraocular pressure at an equivalent level to isoflurane and propofol during unstressed non-ophthalmic surgery. Br J Anaesth 1998;80 (2):243–4.
- [27] Sator-Katzenschlager S, Deusch E, Dolezal S, Michalek-Sauberer A, Grubmuller R, Heinze G, et al. Sevoflurane and propofol decrease intraocular pressure equally during non-ophthalmic surgery and recovery. Br J Anaesth 2002;89 (5):764–6.
- [28] Kaur G, Sharma M, Kalra P, Purohit S, Chauhan K. Intraocular pressure changes during laparoscopic surgery in trendelenburg position in patients anesthetized with propofol-based total intravenous anesthesia compared to sevoflurane anesthesia: a comparative study. Anesth Essays Res 2018;12(1):67–72.
- [29] Seo KH, Kim YS, Joo J, Choi JW, Jeong HS, Chung SW. Variation in intraocular pressure caused by repetitive positional changes during laparoscopic colorectal surgery: a prospective, randomized, controlled study comparing propofol and desflurane anesthesia. J Clin Monit Comput 2018;32 (6):1101–9.
- [30] Yoo YC, Shin S, Choi EK, Kim CY, Choi YD, Bai SJ. Increase in intraocular pressure is less with propofol than with sevoflurane during laparoscopic surgery in the steep Trendelenburg position. Can J Anaesth 2014;61(4):322–9.
- [31] Asuman AO, Baris A, Bilge K, Bozkurt S, Nurullah B, Meliha K, et al. Changes in intraocular pressures during laparoscopy: a comparison of propofol total intravenous anesthesia to desflurane-thiopental anesthesia. Middle East J Anaesthesiol 2013;22(1):47–52.
- [32] Hwang JW, Oh AY, Hwang DW, Jeon YT, Kim YB, Park SH. Does intraocular pressure increase during laparoscopic surgeries? It depends on anesthetic drugs and the surgical position. Surg Laparosc Endosc Percutan Tech 2013;23 (2):229–32.
- [33] Park SH, Kim MH, Kim HJ, Park HP, Jeon YT, Hwang JW. Intraocular pressure changes during gynecologic laparoscopy in patients anesthetized with propofol versus desflurane. Anesth Pain Med 2006;1(2):106–10.
- [34] Son YS, Oh SC, Chung KD, Kim KH, Yoon KJ. A Comparison of the effects of propofol and sevoflurane anesthesias on intraocular pressure during laparoscopic hysterectomy. Korean J Anesthesiol 2005;48(1):10–4.
- [35] Schäfer R, Klett J, Auffarth G, Polarz H, Völcker HE, Martin E, et al. Intraocular pressure more reduced during anesthesia with propofol than with sevoflurane: Both combined with remifentanil. Acta Anaesthesiol Scand 2002;46(6):703–6.
- [36] Moffat A, Cullen PM. Comparison of two standard techniques of general anaesthesia for day-case cataract surgery. Br J Anaesth 1995;74(2):145–8.
- [37] Mets B, Salmon JF, James MFM. Continuous intravenous propofol with nitrous oxide for ocular surgery. A comparison with etomidate, alfentanil, nitrous oxide and isoflurane. S Afr Med J 1992;81(10):523–6.
- [38] Guedes Y, Rakotoseheno JC, Leveque M, Mimouni F, Egreteau JP. Changes in intra-ocular pressure in the elderly during anaesthesia with propofol. Anaesthesia 1988;43(Suppl):58–60.
- [39] Polarz H, Bohrer H, Von Tabouillot W, Martin E, Tetz M, Volcker HE. Intraocular pressure during anaesthesia with isoflurane versus propofol/alfentanil. Anasthesiol Intensivmed Notfallmed Schmerzther 1995;30(2):96–8.
- [40] Mirkheshti A, Shojaei SP, Rabei HM, Mirzaei M, Moghaddam MJ. Comparison of propofol and isoflurane effects on intraocular pressure in patients undergoing lumbar disc surgery. Br J Anaesth 2012;108:pp. ii443.
- [41] Sugata A, Hayashi H, Kawaguchi M, Hasuwa K, Nomura Y, Furuya H. Changes in intraocular pressure during prone spine surgery under propofol and sevoflurane anesthesia. J Neurosurg Anesthesiol 2012;24(2):152–6.
- [42] Kim YS, Han NR, Seo KH. Changes of intraocular pressure and ocular perfusion pressure during controlled hypotension in patients undergoing arthroscopic shoulder surgery: A prospective, randomized, controlled study comparing propofol, and desflurane anesthesia. Medicine (Baltimore) 2019;98(18). pp. e15461.

- [43] Yamada MH, Takazawa T, Iriuchijima N, Horiuchi T, Saito S. Changes in intraocular pressure during surgery in the lateral decubitus position under sevoflurane and propofol anesthesia. J Clin Monit Comput 2016;30(6):869–74.
- [44] Robinson R, White M, McCann P, Magner J, Eustace P. Effect of anaesthesia on intraocular blood flow. Br J Ophthalmol 1991;75(2):92–3.
- [45] Ozkose Z, Ercan B, Unal Y, Yardim S, Kaymaz M, Dogulu F, et al. Inhalation versus total intravenous anesthesia for lumbar disc herniation: comparison of hemodynamic effects, recovery characteristics, and cost. J Neurosurg Anesthesiol 2001;13(4):296–302.
- [46] Kim SH, Lee SH, Shim SH, Kim JS, Kwak SD, Kim CS, et al. Effects of etomidate, propofol and thiopental sodium on intraocular pressure during the induction of anesthesia. Korean J Anesthesiol 2000;39(3):309–13.
- [47] Reza Sahraei HKJ, Adelpour Mohsen, Kalani Navid, Eftekhareian Fatemeh. The comparison of the influence of thiopental and propofol on intraocular pressure during induction of anesthesia in intubated patients under cataracct surgery. Int J Med Res Health Sci 2016;5(7S):147–51.
- [48] Mirakhur RK, Shepherd WF, Darrah WC. Propofol or thiopentone: effects on intraocular pressure associated with induction of anaesthesia and tracheal intubation (facilitated with suxamethonium). Br J Anaesth 1987;59(4):431–6.
- [49] Awad H, Santilli S, Ohr M, Roth A, Yan W, Fernandez S, et al. The effects of steep trendelenburg positioning on intraocular pressure during robotic radical prostatectomy. Anesth Analg 2009;109(2):473–8.
- [50] Johnson DS, Crittenden DJ. Intraocular pressure and mechanical ventilation. Optom Vis Sci 1993;70(7):523-7.
- [51] Bang SR, Lee SE, Ahn HJ, Kim JA, Shin BS, Roe HJ, et al. Comparison of respiratory mechanics between sevoflurane and propofol-remifentanil anesthesia for laparoscopic colectomy. Korean J Anesthesiol 2014;66 (2):131–5.
- [52] Salihoglu Z, Demiroluk S, Demirkiran O, Emin I, Kose Y. Effects of sevoflurane, propofol and position changes on respiratory mechanics. Middle East J Anaesthesiol 2004;17(5):811–8.
- [53] Nyktari V, Papaioannou A, Volakakis N, Lappa A, Margaritsanaki P, Askitopoulou H. Respiratory resistance during anaesthesia with isoflurane, sevoflurane, and desflurane: a randomized clinical trial. Br J Anaesth 2011;107 (3):454–61.
- [54] Viinamki O, Punnonen R. Vasopressin release during laparoscopy: role of increased intra-abdominal pressure. Lancet 1982;1(8264):175–6.
- [55] Joris JL, Chiche JD, Canivet JL, Jacquet NJ, Legros JJ, Lamy ML. Hemodynamic changes induced by laparoscopy and their endocrine correlates: effects of clonidine. J Am Coll Cardiol 1998;32(5):1389–96.
- [56] Berg K, Wilhelm W, Grundmann U, Ladenburger A, Feifel G, Mertzlufft F. Laparoscopic cholecystectomy–effect of position changes and CO2 pneumoperitoneum on hemodynamic, respiratory and endocrinologic parameters. Zentralbl Chir 1997;122(5):395–404.
- [57] Gondim EL, Liu JH, Costa VP, Weinreb RN. Exogenous vasopressin influences intraocular pressure via the V(1) receptors. Curr Eye Res 2001;22(4):295–303.
- [58] Wallace I, Moolchandani J, Krupin T, Wulc A, Stone RA. Effects of systemic desmopressin on aqueous humor dynamics in rabbits. Invest Ophthalmol Vis Sci 1988;29(3):406–10.
- [59] Shirasaka T, Yoshimura Y, Qiu DL, Takasaki M. The effects of propofol on hypothalamic paraventricular nucleus neurons in the rat. Anesth Analg 2004;98(4):1017–23. table of contents.
- [60] Inoue Y, Shibuya I, Kabashima N, Noguchi J, Harayama N, Ueta Y, et al. The mechanism of inhibitory actions of propofol on rat supraoptic neurons. Anesthesiology 1999;91(1):167–78.
- [61] Leighton KM, Lim SL, Wilson N. Arginine vasopressin response to anaesthesia produced by halothane, enflurane and isoflurane. Can Anaesth Soc J 1982;29 (6):563–6.

- [62] Hwang JW, Jeon YT, Kim JH, Oh YS, Park HP. The effect of the lateral decubitus position on the intraocular pressure in anesthetized patients undergoing lung surgery. Acta Anaesthesiol Scand 2006;50(8):988–92.
- [63] Lee JY, Yoo C, Jung JH, Hwang YH, Kim YY. The effect of lateral decubitus position on intraocular pressure in healthy young subjects. Acta Ophthalmol 2012;90(1):e68–72.



Chun-Yu Chang obtained his MD's degree from Tzu Chi University, Taiwan. His research area includes anesthesiology, pain medicine, critical care medicine, emergency care medicine, and systematic review and meta-analysis methodology.



Yung-Jiun Chien obtained her MD's degree from Tzu Chi University, Taiwan. She is currently undergoing residency training in physical medicine and rehabilitation at Taipei Tzu Chi Hospital, Taiwan.



Meng-Yu Wu obtained his MD's degree from Tzu Chi University, Taiwan. He is currently undergoing residency training in emergency medicine at Taipei Tzu Chi Hospital, Taiwan. He has participated in more than 10 research projects and published more than 30 publications in internationally recognized peer-reviewed journals. His research area included carcinogenesis, emergency and critical care medicine. The detail information is provided in lab website: https://sites.google.com/view/wumengyu.